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ABSTRACT 
The aim of this thesis was to investigate the role of endogenous male sex hormones on 
the neuroeffector mechanisms and vascular remodeling in the rat mesenteric artery, 
thus tackling the two mechanisms that control peripheral vascular resistances: vascular 
tone and vascular structure.  
Previous studies on vascular tone have reported that orchidectomy does not modify the 
vasoconstrictor response induced by electrical field stimulation (EFS), although the 
response to exogenous noradrenaline (NA) is diminished, suggesting that EFS-induced 
NA release could be increased in arteries from orchidectomized rats. Besides, pre-
junctional β-adrenoceptors can up-regulate the release of NA and neuronal nitric oxide 
(NO). Since female sex hormones have been reported to modulate the function of 
postsynaptic β-adrenoceptors in rat mesenteric arteries, we hypothesized that that male 
sex hormones could influence presynaptic β-adrenoceptor function, thereby affecting 
NA and neuronal NO release.  
Modulation of the release and function of thromboxane A2 (TXA2) by male sex 
hormones has been previously described, although its role in the response to EFS had 
not been studied yet. Therefore we analyzed the effect of endogenous male sex 
hormones on the EFS-induced release of TXA2 as well as its role in the vasoconstrictor 
response to EFS.  
Vascular structure also determines vascular resistances. Sex hormones are known to 
influence the mechanisms controlling vascular structure, although their effect on the 
eutrophic inward remodeling has not been elucidated yet. Thus, the possible preventive 
effect of testosterone on inward remodeling induced by sustained vasoconstriction was 
tested in small mesenteric arteries from male rats. Since transglutaminase 2 (TG2) is 
involved in inward remodeling the role of this enzyme was also investigated. 
For the studies on vascular tone, endothelium denuded mesenteric arteries from control 
and orchidectomized Sprague-Dawley rats were used.  The effect of β-adrenoceptors 
activation and the role of TXA2 in the vasoconstrictor response induced by EFS were 
analyzed. NA and neuronal NO release induced by EFS were measured, and the role of 
β-adrenoceptors and TXA2 on the release of these neurotransmitters was analyzed. 
EFS-induced TXA2 and prostaglandin I2 (PGI2) release were also measured on both 
groups of rats. 
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The results show that orchidectomy does not alter EFS-induced NA release, but it does 
increase EFS-induced TXA2 release which would account for the maintenance of the 
EFS-induced vasoconstrictor response in spite of the decreased sensitivity to NA. β-
adrenoceptor activation increases NO and NA release only in segments from 
orchidectomized rats confirming that male sex hormones influence β-adrenoceptor 
function. Orchidectomy also modifies the role of TXA2 in the EFS-induced response, 
affecting at least two mechanisms, the NO release and response, and the PGI2 release. 
In the control group, inhibition of TXA2 formation decreases the EFS-response by 
increasing NO release and response, while in segments from orchidectomized rats, 
inhibition of TXA2 formation does not alter the response to EFS by increasing the 
release of PGI2 release, which mediates vasoconstriction. 
For the studies on vascular remodeling, small mesenteric arteries from Wistar rats were 
used. Testosterone induced a dose-dependent vasodilation in arteries from male rats, 
which was inhibited by preincubation with the NO synthase inhibitor Nω-Nitro-L-arginine 
methyl ester hydrochloride (L-NAME), indicating that testosterone induced NO release. 
When arteries were cannulated, pressurized, and kept in organ culture with endothelin-1 
(ET-1) for three days we observed inward remodeling. This was significantly inhibited by 
testosterone and by the transglutaminase 2 (TG2) inhibitor L682.777. ET-1 did not 
significantly modify the TG2 activity and this was not modified by incubation with 
testosterone. It was concluded that testosterone prevent constriction-induced inward 
remodeling through mechanisms other that inactivation of TG2. 
In summary, this thesis show that vascular function is under the influence of gonadal 
function. Orchidectomy modifies the neuronal control of vascular tone through 
modulating the sensitivity of presynaptic β-adrenergic receptors and the balance 
between TXA2 and PGI2. The thesis also shows that in male rats, physiological 
concentrations of testosterone inhibit inward remodeling induced by chronic 
vasoconstriction. Mechanisms other that inactivation of TG2 seem to be involved in this 
inhibition. 
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RESUMEN 
El objetivo de esta tesis fue analizar el papel de las hormonas sexuales masculinas en 
el control neuronal del tono vascular y en el remodelado vascular en la arteria 
mesentérica de rata, analizando por tanto los dos mecanismos que determinan en 
mayor medida las resistencias periféricas vasculares: el tono y la estructura vasculares. 
Con respecto al tono vascular, trabajos previos han puesto de manifiesto que la 
ausencia de hormonas sexuales masculinas no modifica la contracción inducida por 
estimulación eléctrica (EE) en la arteria mesentérica de rata. Sin embargo, la 
contracción inducida por la administración de noradrenalina (NA) exógena es menor en 
arterias procedentes de animales castrados, sugiriendo un aumento de la liberación del 
neurotransmisor en ausencia de hormonas sexuales masculinas. Por otra parte, 
trabajos previos han mostrado que los estrógenos modulan la función de los receptores 
β-adrenérgicos, y éstos a su vez facilitan la liberación de NA y óxido nítrico (NO), por lo 
que se puede especular que los andrógenos también regulen la función de estos 
receptores.  
Estudios previos han mostrado que la orquidectomía modula también la liberación y 
función de tromboxano A2 (TXA2), aunque el papel de este prostanoide en la respuesta 
contráctil inducida por EE no se conoce todavía. Por ello se analizó el efecto de las 
hormonas sexuales masculinas endógenas sobre la participación del TXA2 en la 
respuesta vasoconstrictora inducida por EE y sobre la liberación de TXA2 inducida por 
EE. 
Las hormonas sexuales también modulan la estructura vascular. Sin embargo, el efecto 
de éstas sobre el remodelado hacia el interior (inward remodeling), no ha sido 
estudiado. Por tanto se analizó el posible efecto preventivo de la testosterona sobre el 
remodelado hacia el interior inducido por vasoconstricción sostenida en arterias 
mesentéricas de resistencia de ratas macho. Puesto que se ha demostrado que la 
enzima transglutaminasa 2 (TG2) está implicada en este tipo de remodelado, se analizó 
su participación en el efecto de la testosterona sobre el remodelado. 
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En los estudios sobre el tono vascular, se utilizaron segmentos desendotelizados de 
arteria mesentérica de ratas macho controles y orquidectomizadas de la cepa 
Sprague–Dawley. En ellos se analizó el efecto de la orquidectomía sobre la activación 
de los receptores β-adrenérgicos en la respuesta vasoconstrictora inducida por EE. Se 
midió también la liberación de NA y NO neuronal inducida por EE, analizando el papel 
de los receptores β-adrenérgicos y del TXA2 en la liberación de dichos 
neurotransmisores. Asimismo, se analizó la liberación de TXA2 inducida por EE, así 
como el efecto de este prostanoide sobre la liberación de prostaglandina I2 (PGI2) 
inducida por EE en ambos grupos de animales. 
Los resultados obtenidos muestran que la orquidectomía no modifica la liberación de 
NA en respuesta a la EE, pero si incrementa la liberación de TXA2, lo cual explica el 
mantenimiento de la respuesta vasoconstrictora inducida por EE a pesar de que la 
sensibilidad a la NA está disminuida en segmentos de animales orquidectomizados. La 
activación de los receptores β-adrenérgicos incrementa la liberación de NA y NO sólo 
en segmentos de ratas orquidectomizadas, confirmando que las hormonas sexuales 
masculinas modulan la función de los receptores β-adrenérgicos. La orquidectomía 
también modifica el papel del TXA2 endógeno sobre la respuesta contráctil inducida por 
EE, afectando al menos a dos mecanismos, la liberación y respuesta al NO y la 
liberación de PGI2. En animales controles, el TXA2 incrementa la contracción inducida 
por EE, mediante la disminución de la liberación y la respuesta al NO. En animales 
orquidectomizados la respuesta contráctil inducida por EE permanece inalterada tras la 
inhibición de la formación del TXA2, debido a un incremento en la liberación de PGI2 
que tiene un efecto vasoconstrictor. 
En el estudio de remodelado vascular se utilizaron arterias mesentéricas de resistencia 
de ratas Wistar. La testosterona indujo una respuesta vasodilatadora dosis-dependiente 
que fue inhibida por la incubación previa con el inhibidor de la síntesis de NO, Nω-Nitro-
L-arginine methyl éster hydrochloride (L-NAME), confirmando que la testosterona 
induce la liberación de NO. El mantenimiento de la las arterias presurizadas, en medio 
de cultivo durante 3 días, e incubadas con endotelina (ET-1) indujo remodelado hacia el 
interior, que fue significativamente menor cuando las arterias se incubaron en 
presencia de testosterona. El remodelado vascular inducido también disminuyó 
significativamente por la presencia del inhibidor de la TG2, L682.777. La actividad TG2 
no se modificó por la ET-1 y a su vez la testosterona no modificó este efecto. 
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Estos resultados muestran que la testosterona inhibe el remodelado hacia el interior 
inducido por vasoconstricción crónica a través de mecanismos distintos de la 
inactivación de TG2.  
En definitiva, esta tesis muestra que la función vascular está influenciada por la función 
gonadal. La orquidectomía modifica el control neuronal del tono vascular mediante la 
modulación de la sensibilidad de los receptores β-adrenérgicos presinápticos y el 
balance entre el TXA2 y la PGI2. Esta tesis muestra también que concentraciones 
fisiológicas de testosterona inhiben el remodelado vascular inducido por la 
vasoconstricción crónica y que esta inhibición no parece ser debida a la inhibición de la 
actividad de la TG2. 
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CARDIOVASCULAR DISEASE 
Cardiovascular diseases are the major cause of early mortality and morbidity in 
industrialized countries [1]. In the European Union, they account for 42 percent of all 
deaths in the total population [2]. Lifestyles are often affected by these diseases, 
resulting in disability and/or deterioration in quality of life. Because of the impact of 
cardiovascular disease, national and European health goals and targets have been 
developed and are currently being implemented to study the biological mechanisms 
underlying cardiovascular diseases. 
Many risk factors associated with cardiovascular events have been established in 
population analyses. These include metabolic factors (total cholesterol, HDL 
cholesterol, fasting blood glucose), biological factors (blood pressure) and lifestyle 
factors (tobacco smoking, sedentarism, diet), all of which are modifiable, beyond the 
non-modifiable factors, such as age and male gender [3]. It is well known that diseases 
of the circulatory system are more common at advanced ages; in Europe, 81 percent of 
male deaths and 94 percent of female deaths due to this disease occur in subjects over 
65 years [2]. Male gender is also considered a risk factor for cardiovascular disease, but 
the reason for this is not completely understood. Supported by the fact that clinical and 
epidemiological data show that the prevalence of cardiovascular diseases is higher in 
men compared to age-matched women [4] (Figure 1), the idea that male hormones 
were deleterious while female sex hormones were cardioprotective has been long time 
established in the scientific community [5-7]. However, the inverse correlation between 
cardiovascular disease and low serum levels of androgens in men has been addressed 
several times [8-10] and currently, it is widely accepted that both male and female sex 
hormones are vascular protective in their respective genders [11-18]. In women, the 
prevalence of diseases of the vascular system increases notably after menopause 
[17,19]. 
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Figure 1. Incidence of cardiovascular disease* by age and sex (FHS, 1980–2003). *Coronary heart 
disease, heart failure, stroke, or intermittent claudication. With permission from Roger et al. [4]. 
 
Vascular diseases are also strongly associated with increased blood pressure [20, 21] 
because this situation lowers blood flow to certain tissues by increasing vascular 
resistance. Factors determining vascular resistances are described by the formula 
below, which is the result of combining Ohm´s law (pressure= flow x resistance) with the 
Poiseuille- Hagen formula, 
R = resistance 
         Ƞ = viscosity 
    R=
8ηL
πr4
    r = radius of tube 
         L = length of tube 
Considering that vascular length can be regarded as constant in most beds and blood 
viscosity is constant under most conditions and since flow varies directly and resistance 
inversely with the fourth power of the radius, blood flow and resistance in vivo are 
markedly affected by small changes in the calibre of the vessels [20, 22]. Thus, lumen 
diameter strongly determines the functional participation of arteries, as it determines 
their resistance to blood flow. Hence, the increase in vascular resistance is mainly due 
to a decrease in the vascular calibre, that is, a general narrowing of the vessel.  
Modulation of vascular calibre is determined by both vascular tone and structure. 
Currently, it is becoming clear that vascular tone and vascular structure are highly 
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interrelated so that changes in tone affect the structure of the vessel and vice versa [23, 
24]. The present thesis analyzes the effect of sex hormones on mechanisms regulating 
vascular tone and vascular structure, which are the two factors that determine vascular 
calibre, and thus vascular resistance and blood flow.  
The splanchnic circulation, composed by the vessels supplying the abdominal viscera, 
plays a critical role in the control of the systemic blood pressure, as it collects the 
biggest volume of blood - 60% of the cardiac output - available in the circulatory system 
[25], so mesenteric arteries are important contributors to global vascular homeostasis. 
 
GENERAL STRUCTURE OF THE VASCULAR WALL 
Arteries are anatomically and functionally organized in three layers of tissue; intima, 
media and adventitia (Figure 2). Each one exerts its own influence on both the 
vasomotor control and the vascular structure, although the final effect is the result of the 
interrelated participation of the three layers. The anatomical organisation of the artery 
vessel wall was fully described by Rhodin [26].  
The tunica intima delimits the vessel wall towards the lumen of the vessel and 
comprises the endothelium consisting of a simple and plain epithelium and its 
corresponding basal lamina of connective tissue. Above the connective tissue, it can be 
found the internal elastic lamina, which delimits the tunica intima from the tunica media. 
The endothelium plays a crucial role on the control of the vascular function, as it is not 
only a mechanical barrier, but also acts as a receptor and transmitter of signals between 
blood and other components of the vascular wall. Endothelial cells have exocrine, 
paracrine and autocrine effects, and they are involved in the regulation of vascular tone, 
vasculogenesis and angiogenesis, blood coagulation, fibrinolysis, and inflammation [27]. 
Endothelial cells are sensitive to hemodynamic changes such as pressure or shear 
stress forces, and to circulating chemical messengers. They respond to these signals by 
secreting different growth factors and vasoactive substances, among which it is worth 
noting vasodilator factors such as nitric oxide (NO) and prostacyclin (PGI2) which also 
inhibit platelet aggregation [28], and endothelium derived hyperpolarizing factor (EDHF) 
[29]. Main vasoconstrictor factors released from the endothelium are endothelin-1 (ET-
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1) and vasoconstrictor prostanoids such as thromboxane A2 (TXA2) and prostaglandin 
E2 (PGE2)[27, 30, 31].  
 
 
 
 
 
 
 
Figure 2. General structure of the artery vessel wall. From 
http://www.lab.anhb.uwa.edu.au/mb140/corepages/vascular/vascular.htm 
 
The tunica media is formed by a layer of circumferential smooth muscle and variable 
amounts of connective tissue that forms the extracellular matrix. A second layer of 
elastic fibres, the external elastic lamina, is located over the smooth muscle. It delimits 
the tunica media from the tunica adventitia. Smooth muscle cells can also release 
different vasoactive substances [26, 32]. 
The tunica adventitia consists mainly of connective tissue fibres. The tunica adventitia 
blends with the connective tissue surrounding the vessel. This layer can be fenestrated 
to facilitate blood irrigation to the vessel wall through the vasa vasorum. Adventitia also 
receives and fixates the neuronal axons that innervate the muscular tissue, also called 
perivascular nerves [26, 33]. The adventitia also plays an active role in the regulation of 
vascular structure and tone through the release of factors such as fatty acids, different 
adipokines [34, 35] such as leptine [36], adipose derived relaxing factor (ADRF) [37], 
and reactive oxygen species (ROS) [38, 39]. 
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MECHANISMS REGULATING VASCULAR TONE 
Vascular tone is determined by an equilibrium in which endothelial factors, smooth 
muscle cells and innervation play important roles. In the mesenteric artery, which 
strongly modulates the control of global peripheral resistance, vascular tone is chiefly 
driven through a dual regulation mechanism involving both the endothelial and neuronal 
systems [40]. The endothelium may play a greater role in the response of blood vessels 
to local changes, while perivascular nerves may participate mainly in the integrated 
regulation of blood flow with the whole organism. 
Nitric oxide 
NO was first discovered in 1987 as a new second messenger [41] and then in 1990 it 
was also described as a new neurotransmitter [42]. It is one of the most widely studied 
factors in the regulation of vascular tone, and the mechanisms driving its synthesis, 
release, metabolism and mode of action are very well known [30, 43]. NO is a gaseous 
free radical that plays a vital role as a cell signalling molecule in the vascular, nervous 
and immune systems [44]. It is synthesized by enzymes called nitric oxide synthases 
(NOS), from L-arginine, which is oxidized to L-citruline using nicotinamide adenine 
dinucleotide phosphate (NADPH) as an electron donor [45]. Three different isoforms of 
NOS have been described in mammals, coded from different genes, localized in 
different chromosomes, and functionally catalogued into constitutive or inducible 
expressed [46]. There are two constitutive isoforms the activity of which is dependent on 
intracellular Ca2+ levels. One of them, endothelial NOS (eNOS), is present in the 
endothelium, endocardium and myocardium, and the other, neuronal NOS (nNOS), is 
primarily present in the central and peripheral nervous system and also in 
cardiomyocytes [47]. The third isoform, inducible NOS (iNOS), is a high-output Ca2+-
independent NOS, the expression of which can be induced in a wide range of cells and 
tissues by cytokines or bacterial endotoxins [48]. 
Under physiological conditions, NO produced by constitutive NOS regulates vascular 
permeability and blood flow [49]. Thus, NO is not only released following stimulation, but 
also plays an important role in the maintenance of basal vascular tone, as demonstrated 
by the fact that infusion of an NOS inhibitor, L-NG-monomethyl arginine (L-NMMA), 
increases resting blood pressure [50]. NO is also an anti-proliferative, anti-inflammatory 
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and anti-thrombotic agent [51]. Under inductive conditions, high levels of NO 
synthesized by iNOS in activated immune cells can mediate anti-bacterial and anti-
tumor functions, thus participating in the immune response [52].  
Released NO diffuses to the smooth muscle cells where it stimulates soluble guanylate 
cyclase, resulting in an increased formation of cyclic guanosine monophosphate 
(cGMP) [53]. cGMP activates protein kinase G (PKG), which prevents the entry of Ca2+ 
into the cytoplasm by inhibiting the L type-Ca2+ channels in the cell membrane and 
activating the Na+/Ca2+ pump. PKG also activates the Ca2+-ATPase form in the cell 
membrane and the endoplasmic reticulum, to decrease intracellular Ca2+ concentration 
[54]. Besides, cGMP induces other actions that indirectly prevent increases in 
intracellular Ca2+ concentration, such as the activation of potassium (K+) channels that 
hyperpolarize the cell membrane [55, 56] (Figure 3).  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Schematic representation of the mode of action of nitric oxide in the vessel wall. NO can be 
produced under physiological conditions by the nitregic nerve endings through neuronal NOS (nNOS) or 
by endothelial cells through endothelial NOS (eNOS). Released NO diffuses to the smooth muscle cells 
where it stimulates soluble guanylate cyclase, resulting in an increased formation of cyclic GMP (cGMP). 
cGMP activates protein kinase G (PKG), which promotes relaxation of the smooth muscle cells through 
different mechanisms, including activation of Ca2+-ATPase channels from plasmatic cell membrane and 
endoplasmic reticulum, promoting a decrease in the intracellular Ca2+ concentration; and activation of the 
membrane potassium (K+) channels, which mediate membrane hyperpolarization. Adapted with 
permission from http://www.epgonline.org. 
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Innervation 
Although research on the physiologic and pathologic mechanisms of vascular tone 
regulation, especially in the study of  the role of sex hormones, have traditionally 
focused on the endothelial function, there is a great amount of evidence supporting the 
important role of innervation on the vascular homeostasis [32, 57-59]. Indeed, it has 
been hypothesized that under intensive vasoconstriction conditions, some neuronal 
dependent vasodilator mechanisms may be more important than endothelial-dependent 
ones [60]. This relevant participation of nerves gave rise to the concept of the dual 
control of vascular tone by both endothelium and neuronal mechanisms. As such, 
research on the role of sex hormones on vascular function should tackle this question.  
The density of vascular innervation varies considerably between vascular beds in 
different tissues and between different physiological situations [30,61]. Usually, 
innervation density increases as the calibre decreases, so that small arteries possess 
the most intense innervation. The mesenteric artery, which strongly modulates global 
peripheral resistance, is densely innervated. Nerves surround blood vessels forming a 
complex grid-like network termed the perivascular nerve plexus (Figure 4). Perivascular 
nerves do not penetrate smooth muscle cells, but they stay within the media and the 
adventitia [62]. Innervation of arteries is composed of nerves from the autonomic 
neuronal system, consisting mainly in sympathetic, parasympathetic and sensory-motor 
nerves [30]. In the mesenteric artery, sympathetic innervation is composed of 
adrenergic nerve terminals releasing mainly noradrenaline and producing 
vasoconstriction [63]. Sensory-motor nerves are primarily afferent sensory nerves that 
also release neuropeptides, mainly calcitonin gene-related peptide (CGRP), resulting in 
vasodilation [64, 65].  Parasympathetic innervation has a vasodilatory effect and is 
composed of both the cholinergic and nitrergic nerves releasing mainly acetylcholine 
(Ach) and NO respectively [53]. The net nervous effect on the vascular tone is the result 
of the integration of vasoconstrictor and vasodilator influences. Thus, electrical 
stimulation of nerve endings in the mesenteric artery produces a vasoconstrictor 
response that is the integrated result of the release and response to different 
neurotransmitters, mainly NA, NO and CGRP [53, 63, 64]. 
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Figure 4. Confocal laser photomicrographic images showing perivascular nerves in the rat mesenteric 
artery. Images show; (a) the neuronal nitric oxide synthase (nNOS)-like immunoreactivity (LI) in green  
and (b) tyrosine hydroxides (TH)-LI-containing fibers (adrenergic fibers) in red. The horizontal bars 
indicate 100 μm. Modified with permission from Koyama et al. [84]. 
 
Autonomic neuro-effector junctions in blood vessels are atypical, as they contain pre-
junctional membrane thickenings with synaptic vesicles, but without specialized post-
junctional structures. This is probably related to the fact that the periarterial nervous 
plexus is not a fixed network, as it can undergo dynamic changes in response to 
physiologic or may be pathologic changes [66]. Besides, nerves usually contain 
neurotransmitters and cotransmitters that interact and modulate each other, often 
involving synergistic cotranssmision or pre- and post-junctional neuromodulation of 
neurotransmitter release [33, 66]. 
Adrenergic innervation 
The sympathetic control of the vascular resistances has a paramount role on the control 
of the peripheral vascular resistance [67]. Stimulation of sympathetic nerves in the 
splanchnic circulation increases peripheral resistance and mobilizes up to two thirds of 
the reserve blood volume in the veins [68]. Besides, one of the major pathophysiological 
mechanisms of hypertension includes activation of the sympathetic nervous system 
[69]. The activity of this innervation, primarily vasoconstrictor, over the arterial wall is 
exerted by the release of NA. NA release from the adrenergic nerve terminals seems to 
be the major contributor to the contraction induced by electrical field stimulation, as 
preincubation with the α-adrenoceptor antagonist phentolamine strongly inhibits this 
response [70]. 
Adenosine triphosphate (ATP) and neuropeptide Y (NPY) are cotransmitters released 
with NA in these nerves, and they also mediate vasoconstriction [33, 71]. However, its 
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role in the adrenergic-induced contraction does not seem to be very relevant in the rat 
mesenteric bed, as preincubation with the blocker of nerve impulse propagation 
tetrodotoxin, inhibits the contraction induced by electrical field stimulation to a similar 
extent as phentolamine does [70]. 
Upon release, NA binds post-synaptic α1 and α2-adrenoceptors on arterial smooth 
muscle cells, leading to contraction [33]. Stimulation of post-junctional α1-adrenoceptors 
activates the phospholipase C (PLC) through a G protein. PLC catalyzes the 
transformation of phosphatidyl-inositol bisphosphate (PIP2) in diacylglycerol (DAG) and 
inositol triphosphate (IP3), resulting in the release of the stored Ca2+ and the activation 
of the protein kinase C (PKC) respectively, thus producing contraction of the smooth 
muscle cells [72, 73] (Figure 5). Stimulation of post-junctional α2-adrenoceptors inhibits 
the enzyme adenylate cyclase, thus decreasing the cyclic adenosine monophosphate 
(cAMP) levels, which also increases the cytoplasmatic Ca2+ concentration. 
Simultaneously, NA can activate pre-junctional α2-adrenoceptors, which mediate 
inhibition of NA release in a negative feedback mechanism [74, 75] (Figure 6). 
NA can also bind to pre- or post-synaptic β-adrenoceptors. Activation of the former 
facilitates NA release, thus consisting of a positive feedback mechanism [76, 77]. 
Activation of post-synaptic β-adrenoceptors induces relaxation of the smooth muscle 
cells (Figure 6). These receptors are coupled to G proteins that activate the enzyme 
adenylate cyclase thus inducing cAMP formation, which leads to the relaxation of the 
smooth muscle cell [78]. Different subtypes of β-adrenoceptors have been identified. 
Among them, β1-adrenoceptors have high affinity for noradrenaline and are 
predominantly found in heart, brain and adipose tissue, while β2-adrenoceptors have 
low affinity for noradrenaline and are present in the vascular smooth muscle cells [73]. 
More recently, the existence of functional vasodilatory β1-adrenoceptors in the vascular 
wall has also been addressed [79]. β3-subtype adrenoceptors have also been described 
although it has been reported that they are not present in the rat mesenteric artery [79]. 
However, the net effect of adrenergic receptor activation in arteries is vasoconstriction, 
which has been explained by the fact that NA has more affinity to α- than to β-
adrenoceptors, and also because of the increased presence of α- compared to β-
adrenoceptors in the vascular smooth muscle cells [63]. 
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There is great heterogeneity among the subtypes of adrenoceptors present in different 
vascular beds, differing even between strains. But there are also many differences in 
the functional role of adrenoceptors between distinct physiological situations [59, 80, 81] 
supporting the idea of the mobile and adaptative nature of the periarterial nervous 
plexus commented above [66].  
 
 
 
Figure 5. Molecular mechanism of adrenergic-mediated smooth muscle contraction. Norepinephrine from 
sympathetic nerve endings activates receptors on smooth-muscle cells to initiate the cascade of reactions 
that results in elevation of intracellular calcium concentrations and smooth muscle cell contraction. 
Protein kinase C is a regulatory component of the calcium-independent, sustained phase of agonist-
induced contractile responses. Adapted with permission from Lue [82].  
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Nitrergic innervation 
The mesenteric artery possesses perivascular nitrergic innervation that releases NO in 
response to electrical stimulation [83], thus participating in the regulation of vascular 
tone. Because of its chemical characteristics, NO does not have a receptor, as it has a 
half life of 5 seconds and it is a gaseous, small, polar, uncharged molecule. These 
characteristics allow it to diffuse inside the adjacent cells, where it exerts its function 
through stimulating soluble guanylate cyclase, as explained previously (Figure 3). 
Some authors have suggested that neurogenic NO seems not to have a very significant 
role in neurogenic vasodilatation in the rat mesentery [33, 53], although nitrergic nerves 
have been inmunohistochemically detected  [84](Figure 4) and inhibition of neuronal NO 
release by L-NAME in endothelium denuded mesenteric arteries has also been shown 
to increase the contractile response induced by electrical field stimulation [70, 83]. 
Besides, the release of neuronal NO induced by EFS has been demonstrated, since 
tetrodotoxin, which blocks the nerve impulse propagation, abolishes this release [85]. It 
has been suggested that NO release could be up-regulated by pre-junctional activation 
of β-adrenoceptors by NA in the nitrergic nerve endings [83] (Figure 6). 
Sensory innervation 
Previous reports provided evidence that periarterial nerve stimulation of arteries 
produces non-adrenergic non-cholinergic neurogenic vasodilation, which is mediated by 
CGRP [86, 87] (Figure 6). Upon release, CGRP binds to its functional receptor 
consisting of receptor-affinity-modifying protein 1 (RAMP1) associated with calcitonin 
receptor-like receptor (CRLR) [88]. CGRP receptors are present in endothelial cells, 
where they potentiate NO and PGI2 formation and; also in smooth muscle cells, where 
they activate adenylate cyclase increasing cAMP levels and consequently induce 
relaxation [89, 90]. 
Sensory nerves can suppress sympathetic nerve-mediated vasoconstriction by 
releasing CGRP and conversely, sympathetic nerves presynaptically inhibit the release 
of CGRP [64, 91] (Figure 6). Thus, it has been proposed that vasodilator sensory 
nerves, along with vasoconstrictor sympathetic nerves, regulate the tone of the 
mesenteric resistance arteries. Nevertheless, previous studies carried out by my 
research group showed that sensory innervation does not have a role in the 
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vasoconstrictor response to electrical field stimulation in the rat mesenteric artery [70, 
83]. In contrast, a functional role for sensitive innervation has been demonstrated using 
the same methodology in diabetic [58], and in hypertensive male rats[92], but not in 
hypertensive female rats [57]. All these data support the idea that the participation, and 
thus the physiological relevance of sensory-motor innervation varies depending on the 
strain, the physiological situation, and even on gender.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.  Factors influencing the contractile response induced by electrical field stimulation. EFS applied 
to the mesenteric artery induces a contractile response that is the integrated result of the release of 
noradrenaline (NA), nitric oxide (NO) and calcitonin gene-related peptide (CGRP) from adrenergic, 
nitrergic and sensory innervations respectively. 
 
Cholinergic innervation 
Ach release from parasympathetic nerves results in activation of muscarinic receptors 
on vascular smooth muscle cells, inducing contraction of these cells and 
vasoconstriction, but Ach release also activates muscarinic receptors on endothelial 
cells producing NO release that leads to vasodilation [93]. ATP and vasoactive intestinal 
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polypeptide (VIP) have been shown to be co-transmitters with Ach in parasympathetic 
nerves [71]. However Ach containing nerves are not ubiquitously present and it is 
thought that this innervation has very little effect or is even absent in most peripheral 
resistance arteries [33, 53, 94]. In fact, stimulation of cholinergic nerves in the 
mesenteric bed does only produce a small vasodilatation [60]. Therefore it does not 
seem to have relevance in the control of peripheral resistance. Nevertheless, 
cholinergic receptors are ubiquitously expressed in the arterial wall, and endothelial 
cells express the enzymatic machinery for the synthesis and transport of Ach, as well as 
acetylcholinesterase, thus pointing to the existence of an additional intrinsic, non-
neuronal cholinergic system residing in the vascular wall [95]. However, the functional 
relevance of this system remains to be defined. 
Prostanoids 
Prostanoids are metabolites from arachidonic acid very well known for their pivotal 
functions in cellular processes such as inflammation, platelet aggregation and vascular 
tone regulation [96]. They are present in almost all cell types and are involved in many 
vascular pathologies. NO and prostanoid systems are known to modulate each other, 
although modulation of the NO systems by prostanoids has been less studied [97-101]. 
Prostanoids are synthesized from arachidonic acid (AA) which is in turn formed from 
membrane phospholipids through the enzymes phospholipase A2 (PLA2) and 
diacylglycerol lipase. AA is converted to the prostanoid precursor prostaglandin G2 
(PGG2), which is subsequently peroxidized to prostaglandin H2 (PGH2). Both enzymatic 
reactions are catalyzed by the protein cyclooxygenase (COX); its cyclooxigenase 
activity adds two O2 molecules to the AA generating PGG2, whereas the peroxidise 
activity catalyzes the reduction of PGG2 to PGH2 [102] (Figure 7). There are two 
physiologically relevant isoforms of COX: COX-1 is constitutively expressed and 
localized in the endoplasmic reticulum, and COX-2 is inducible and primarily localized in 
the nuclear membrane [103]. Induction of COX-2 occurs in certain cell types in 
response to proinflammatory stimuli, and hence most of the inflammatory functions of 
prostanoids synthesis are attributed to this isoform of COX [96, 104]. A third isoform of 
COX, called COX-3, has been discovered in dogs [105], but it is currently not thought to 
have a physiologically relevant role on prostaglandin synthesis in rodents and 
humans[106]. 
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Bioactive prostanoids are prostaglandin E2 (PGE2), F2α (PGF2α), D2 (PGD2), I2 (PGI2), 
and thromboxane A2 (TXA2). They are formed from PGH2 through their respective 
synthases (Figure 7) [107]. Each prostanoid exerts its action by binding to its specific 
receptor (Figure 7). However, depending on the cell type, the physiologic situation or 
the concentration, ligand-binding can be observed between a given prostanoid and 
other receptors within the family [96]. In this situation, a prostanoid can produce an 
effect opposite to that usually described.  
 
Figure 7. Synthesis pathway of the different bioactive prostanoids from arachidonic acid through the 
enzymatic activity of COX. For each prostanoid, specific receptors and their vasomotor effect upon 
activation are indicated. 
 
Thromboxane A2 
TXA2 is one of the prostanoids produced in the vascular wall that has been most 
studied, due to the importance of its important role in vascular homeostasis. Both 
endothelial [108] and smooth muscle cells [109] synthesize it. TXA2 is a potent 
vasoconstrictor and inductor of platelet aggregation and it is involved in several 
pathologies such as hypertension, atherosclerosis, myocardial infarction and stroke 
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[110, 111]. Thus, TXA2 can participate in the endothelial dysfunction associated with 
cardiovascular disease [112]. TXA2 activates its specific receptor, the TP receptor, 
which is functionally coupled to a G protein. The activation of these components inhibits 
adenylate cyclase, leading to a decrease in cAMP levels [111]. Activation of TP 
receptors also induces the activation of PLC. As commented above, PLC catalyzes the 
transformation of PIP2 in DAG and IP3, resulting in the release of stored Ca2+ and the 
activation of PKC respectively, and this leads to the contraction of the smooth muscle 
cells [72]. The activation of these signalling pathways induces not only platelet 
aggregation and vascular smooth muscle cells contraction but also hypertrophy and cell 
proliferation [96]. 
Prostacyclin. 
Prostacyclin, or PGI2, which is synthesized by the PGI2 synthase [113], induces 
vasodilation and inhibits platelet aggregation on vessels [96]. PGI2 can induce different 
or even opposite effects depending on its concentration and on the G protein to which 
the IP receptor is coupled. Thus, if the IP receptor is coupled to a Gs protein, it 
stimulates when activated, the production of cAMP by activating adenylate cyclase 
[114]. cAMP can act both directly and indirectly on ionic channels, finally producing a 
decrease in cytosolic Ca2+, that leads to smooth muscle cell relaxation. PGI2 can also 
induce vasodilation upon activation of the endothelial IP receptors, which induce NO 
release [115]. On the other hand, IP receptors can couple to Gq and Gi proteins [116], 
which would induce vasoconstriction. Besides, high concentrations of PGI2 have been 
reported to induce vasoconstriction as a result of the activation of TP receptors [117, 
118]. However, the general vasomotor mechanism of PGI2 seems to be the 
counteraction of the effect of TXA2. In fact, it has been described that PGI2 can 
antagonize the effects of TXA2, and it can even reverse hypertrophy induced by the 
TXA2 analogue U-46619 [119]. 
 
Reactive oxygen species 
The formation of ROS is a common feature of normal cell metabolism. ROS generally 
increase vascular tone through their influence on the endothelium, as well as by either 
direct effect on vascular smooth muscle contractility. One of the most important ROS in 
vascular function is superoxide anion (O2-) [120]. Superoxide anion is a negatively-
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charged free radical that undergoes rather selective chemical reactions with 
components of biological systems. Superoxide anion is produced by the reduction of O2 
and is toxic for the cell when is present in high amounts. Because NO has an unpaired 
electron, it can react with O2- producing peroxynitrite (ONOO-) as the result of a 
spontaneous and irreversible chemical reaction [120]. The consequence of this reaction 
is a decrease in NO bioavailability [121] thus attenuating its vasodilator effect, and the 
generation of peroxynitrite, that can potentially interact with regulatory systems of 
biological significance. 
ROS can also contribute to vascular remodeling as they can modify the smooth muscle 
cell phenotype, and alter processes such as growth, migration, cell death, or 
extracellular matrix reorganisation [122]. Excessive ROS production or an insufficient 
antioxidant activity can induce alterations in vascular function. 
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VASCULAR REMODELING 
Since 1987, when Glagov reported the surprising finding that atherosclerotic arterial 
lumen narrowing is not simply the result of enlargement of atherosclerotic lesions [123], 
the concept emerged that wall structure can change to maintain the appropriate lumen 
size to permit normal blood flow, and this was termed vascular remodeling [124].This 
ability of arteries to adapt is central to most arterial diseases. Nevertheless, the inability 
of vessels to remodel appropriately is considered a form of ‘vascular failure’ that can 
lead to pathologic states such as hypertension or atherosclerosis [125, 126].  
Mulvany proposed a terminology to classify structural changes in hypertensive vessels 
based on changes in lumen diameter (inward or outward) and wall area 
(increased=hypertrophic, decreased=hypotrophic, no change=eutrophic) [127] (Figure 
8). Irrespective of the mechanism responsible, the main feature of hypertensive 
vascular remodeling is the increased media/lumen ratio, which can occur with or without 
growth (i.e. hypertrophic or eutrophic). Patients and animal models with essential 
hypertension exhibit predominantly eutrophic inward remodeling, which allows the 
vessels to maintain an increased resistance without increasing vascular tone [128].  
Global peripheral resistance is mainly determined by the resistance vessels, consisting 
of the small arteries (arteries with diameter < 300 µM) and the arterioles (the arteries 
just before the capillaries) [129]. Increased peripheral resistance is a common 
parameter in essential hypertension, and current evidence indicates that it is due in part 
to a general narrowing of the resistance vessels [130].   
Inward remodeling of small vessels is characterized by a decrease in the outer and 
lumen diameter, and an increase in the media/lumen ratio [131], with no change in the 
wall cross sectional area. This vessels are stiffened, which means that compared to 
normal vessels, they are not able to increase its diameter in response to increases of 
pressure [132].  
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Figure 8. Patterns of vascular remodeling. Classification refers to changes on the lumen diameter (inward 
or outward) and vessel cross-sectional area (hypertrophic, hypotrophic or eutrophic). Adapted from 
Mulvany [127]. 
Vascular structure is studied with the smooth muscle cells relaxed, and usually with 
exposure of the vessels to a given intravascular pressure [24, 128]. Mechanisms 
involved in vascular remodeling have been investigated in organ culture, where vessels 
are cannulated and maintained under pressurized conditions during three days, 
retaining their viability [132]. In this series of studies, Bakker et al. have reported that 
maintained constriction is necessary for inducing remodeling [133, 134]. This 
remodeling is eutrophic, as it is not the result of any change in the cross-sectional wall 
area. Indeed, this remodeling could also be induced in the presence of growth inhibitors 
[134]. These experiments support the idea that eutrophic inward remodeling, could be 
the result of sustained vasoconstriction [24, 135]. In fact, the early stages of 
hypertension are thought to be associated with increased sympathetic activity (which 
mediates vasoconstriction, as explained below) and thus presumably increased 
vascular tone [136]. These authors suggested that eutrophic remodeling, which is seen 
in essential hypertension, is the result of the reorganization of the wall material during 
the constriction period, in such a way that the initial active narrowing of the lumen would 
become permanent and passive [133] (Figure 9). This hypothesis supports the idea of 
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the interrelation between vascular tone and structure [24]. Interestingly, active 
constriction of the lumen diameter is mandatory for inducing remodeling, since passive 
narrowing of lumen diameter (i.e. decreasing intravascular pressure), does not induce 
any remodeling and besides, vasodilatation prevents inward remodeling [133]. This idea 
correlates well with data showing a decrease in the remodeling process of hypertensive 
subjects after treatment with vasodilators, but not after reducing blood pressure [137]. 
 
Figure 9. Schematic representation of the hypothesis that links vasoconstriction to inward remodeling. a 
Segment of the vessel wall in a relaxed state, showing smooth muscle cells in yellow, structural elements 
form the extracellular cell matrix in black, and cross-links in blue. b contracted vessels where the 
shortening of the SMC narrows the lumen. c during chronic vasoconstriction extracellular matrix 
reorganizes and forms new cross-links. d Upon vascular relaxation, passive forces from the newly 
organized extracellular matrix narrow the lumen, preventing dilation to the original diameter. With 
permission from van den Akker et al. [24]. 
Structures involved in the process described above are thought to be the components of 
the cytoskeleton along with membrane integrins of smooth muscle cells and elements of 
the extracellular cell matrix (ECM), particularly collagen and elastin. Integrins are 
proteins that connect the cytoskeleton with the ECM and also act   as receptors. 
Collagen is mainly responsible for providing strength to the vessel wall, while elastin, is 
the major component of the elastic fibers. The quantity and quality of each one of these 
components determines in part the mechanical properties of vascular structure. 
Fibronectins are attached to integrins and can also modulate characteristics of the ECM 
[24, 135, 138, 139]. Regarding the hypothesis of the vascular tone driving inward 
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eutrophic remodeling, Martinez-Lemus et al. support that during sustained 
vasoconstriction, there may be a re-positioning of vascular smooth muscle cells over the 
reduced lumen diameter, and they confer a role to the cytoskeleton and integrins in the 
remodeling process [135]. 
It should be noted that although there is no change in the vessel wall mass in the 
eutrophic remodeling described, smooth muscle cell proliferation and apoptosis should 
not be discarded as part of the remodeling process [140]. 
Transglutaminase 2 in vascular remodeling 
It has been recently reported that transglutaminase 2 (TG2) is involved in the inward 
remodeling of small vessels [141]. Thus, inward remodeling induced by low blood flow 
in vivo, or by chronic vasoconstriction in vitro can be inhibited by TG2 inhibitors [142]. 
Transglutaminases are a group of enzymes known for their ability to provide mechanical 
strength to the tissues by catalyzing protein cross-links [143]. The most important cross-
link catalyzed by transglutaminases in vascular remodeling is the Nε(γ-glutamyl)lysine 
isopeptide bond, which stabilizes the ECM. TG2 is involved in wound healing, cell 
adhesion, apoptosis and matrix reorganisation, and recent reports have suggested that 
it could also play a key role in vascular remodeling [141]. These authors proposed that 
TG2 could fixate the extracellular matrix into a more narrowed state during chronic 
vasoconstriction, through cross-linking its proteins. They found several extracellular 
substrates for TG2, including fibronectin, collagen and nidogen [144]. TG2 is 
ubiquitously expressed and as such, is present in smooth muscle cells, endothelial cells 
and vessel wall fibroblasts [145]. Its cross-linking activity can be activated by elevated 
intracellular Ca2+, and inhibited by NO and guanosine triphosphate (GTP) [146, 147]. 
Therefore most of TG2 activity may be latent under physiological conditions. 
Overexpression of TG2 alone does not result in intracellular cross-linking [148], 
indicating that its effect depends on its activation. However, activation and translocation 
of the enzyme to the outer face of the vessel wall is necessary to induce remodeling 
[144], supporting the idea that TG2 would cross-link proteins from the extracellular 
matrix. However, the link between sustained constriction and TG2 translocation and 
activation remains unknown, although van den Akker et al. proposed that a reducing 
environment is necessary to induce membrane-bound activity of TG2 [144].  
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Of particular interest for the study on the effect of sex hormones on vascular remodeling 
included in this thesis, is the fact that TG2 can be inhibited by NO through S-
nitrosylation of cysteine residues [147]. In fact, NO donors inhibit vascular remodeling 
induced by exogenous transglutaminase or by an intracellular reducing agent [142, 
144]. Besides, animal models of hypertension induced by L-NAME intake, have inwardly 
remodeled small mesenteric vessels, an effect that was not induced in a 
transglutaminase knockout mice which received the same treatment with L-NAME [149]. 
Therefore, inward remodeling could be present in any pathology associated with 
decreased NO production or bioavailability due to the promotion of TG2 activation. 
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SEX HORMONES 
Sex hormones produce a great variety of biological effects. They induce differentiation 
and cell growth of reproductive tissues, and development and maintenance of 
secondary sexual characters after the beginning of puberty [150]. 
Estrogens (estradiol, estrone and estriol) and progestagens (progesterone) are the main 
female sex hormones, while testosterone is the main male sex hormone, although some 
of its precursors and metabolites can also be of biological relevance [12, 151]. Sex 
steroids are mainly synthesized in gonads and secondarily in the suprarenal cortex from 
cholesterol (Figure 10) [152]. Nevertheless, production of endogenous estrogens and 
androgens from their precursor dehydroepiandrosterone (DHEA) has also been 
described in a number of extragonadal sites such as adipose, epithelial, osseous, 
neuronal and vascular tissues [153, 154]. Besides, testosterone can be converted to 
estradiol by aromatase in the extragonadal sites described above [154].  
 
 
Figure 10. Conventional synthetic pathway of sex hormones.  17beta-hydroxysteroid 
dehydrogenase type 2 (17β-HSD2). Adapted from Ghayee and Auchus [152]. 
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Findings in the last decades have shown that sex hormones play important roles on the 
vascular system [12-15], and hence low serum levels are independently related to 
cardiovascular disease in both genders [11, 16-18]. This protective effect of sex 
hormones can be attributed to their multiple modes of action, such as modulation of the 
lipid profile, vascular tone and vascular structure [13, 15].  
Biological effects of sex hormones can be induced via genomic mechanisms, which 
involve steroid binding to its nuclear or cytosolic receptor, a ligand-activated 
transcription factor, thus modulating gene expression. The genomic effects of estradiol 
in vascular function include promoting endothelial cell growth and inhibiting growth of 
vascular smooth muscle cells [155]. Regarding androgens, some studies have 
suggested that they potentiate vascular smooth muscle cell growth while others suggest 
that they inhibit it [156, 157].   
Sex hormones can also act without involving transcription, through non-genomic effects 
[158]. These effects can be triggered by receptor-dependent as well as receptor-
independent mechanisms. For example, both estradiol and testosterone may induce 
vasodilation in a non-genomic manner by different pathways involving receptor 
dependent and independent mechanisms [12, 155]. However, sex hormones can 
activate different signalling pathways through non-genomic mechanisms that can 
indirectly lead to modifications on the gene expression. 
 
Sex hormones and vascular tone 
Both male and female sex hormones can induce rapid vasodilation in an endothelium 
dependent manner. Acute infusion of estrogen into arteries causes dilatation owing to 
both an increased release of nitric oxide from the endothelium and the inhibition of ion 
channels in the smooth muscle. Increased release of endothelial NO mediated by 
female sex hormones can be mediated by both genomic and non-genomic pathways: by 
rapid signalling with membrane estrogen receptors through the PI-3Kinase/Akt pathway 
resulting in eNOS phosphorylation, and also increasing eNOS expression in a long term 
genomic manner [159]. 
Androgens can also induce endothelial NO-mediated vasorelaxation [12] in a rapid non-
genomic manner, although the mechanism underlying this effect has not yet been 
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established. Whether it activates the release of nitric oxide directly or indirectly through 
aromatization to estrogen remains controversial [15, 159], although some studies have 
specifically evidenced an androgen mediated vasodilation independent from the 
conversion to estrogens [160, 161]. Androgens can also induce rapid non-genomic 
vasodilation by modulation of the vascular smooth muscle cells ion channel function, 
particularly by inhibiting Ca2+ channels and activating K+ channels in the cell membrane 
[160, 162]. 
Neuronal modulation of vascular tone strongly determines peripheral vascular 
resistances. Despite this, the effect of sex hormones on these mechanisms has been 
less studied. In fact, many reviews on the protective effect of sex hormones on vascular 
function do not mention it [11-15]. There is, though, a recent review that specifically 
focuses on the effect of sex hormones on neuroeffector mechanisms, including vascular 
function [67].  
Sex hormones influence the vascular adrenergic function [67, 163], although the 
mechanism by which this modulation occurs is still not fully understood. Positive 
correlations between androgens and parasympathetic activity have been described in 
men [164], and greater vascular resistance has been recorded in men compared to 
women, the difference being attributed to alpha-adrenergic activity [165]. In rat 
mesenteric arteries, orchidectomy decreases the contraction induced by exogenous NA, 
though the vasoconstrictor response to EFS is not modified [70]. Together all these data 
suggest that modulation of the adrenergic activity is one of the mechanisms by which 
androgens can alter peripheral vascular resistances. Female sex hormones also 
modulate vascular adrenergic activity, as it has been suggested that estrogens could 
limit the production of noradrenaline, attenuate the vasoconstrictor response to 
noradrenaline and increase vasodilator β-adrenoceptor sensitivity [67, 80]. 
Regarding nitrergic innervation, studies from my research group have shown that 
mesenteric arteries from orchidectomized rats have decreased nNOS expression, 
although the release of neuronal NO is not changed [70] because nNOS activity is 
increased through PKC activation [85]. However, NO metabolism is higher in segments 
from orchidectomized male rats due to the increased generation of superoxide anion 
(O2-) and peroxynitrite formation [70]. 
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In females, the effect of endogenous sex hormones on the nitrergic innervation has also 
been studied in my laboratory. Results showed that NO release is increased in 
mesenteric segments from ovariectomized rats, and although NO metabolism is higher 
in this group, the net contribution of neuronal NO to the vasoconstrictor response 
induced by electrical stimulation is greater in ovariectomized animals [166], which was 
suggested to be a compensatory mechanism to counteract the loss of endothelial NO 
reported in the same artery [81]. 
Sex hormones also influence TXA2 release and function. Hence, endothelium-mediated 
TXA2 release is increased in arteries form orchidectomized and ovariectomized rats by 
increasing COX-2 expression [101, 167, 168].  Testosterone was also shown to 
increase TXA2 vasoconstrictor response [169] and to increase the density of TP 
receptors in vascular smooth muscle cells [170, 171]. However, the effect of 
orchidectomy on TXA2-induced contractile response depends on the vascular bed, 
since in the mesenteric artery castration did not modify the response to the TXA2 
mimetic U-46619, while it increased this response in aorta [167, 168]. 
Estrogen up-regulates COX-1, but also up-regulates PGI2 synthase expression, thus 
directing prostanoid balance toward increased PGI2 production [172]. Testosterone has 
also been reported to increase PGI2 production through COX-2 up-regulation in diabetic 
rats [173]. 
 
Sex hormones and vascular remodeling 
Since the role of sex hormones on vascular functions has become a theme of great 
interest in the last decades and since most arterial diseases are related to vascular 
structure alterations, the effect of sex hormones on vascular remodeling has also been 
investigated. However, studies concerning sex hormones and vascular remodeling have 
mainly focused on hypertrophic remodeling, thus addressing the role of sex steroids on 
proliferation cascades and growth factors. The majority of these studies show that both 
male and female sex hormones play antiproliferative and anti-inflammatory roles, thus 
inhibiting the hypertrophic remodeling related to atherosclerotic lesions. Estrogens 
attenuate atherosclerosis, inhibits oxidative stress, and attenuate vascular remodeling 
via inhibition of proliferation signalling pathways [174]. Progesterone also attenuates 
vascular hypertrophic remodeling [175]. Regarding male sex hormones, low serum 
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levels of testosterone are inversely related to the severity of coronary atherosclerosis 
[176] carotid intima-media thickening [177, 178] and arterial stiffness [179]. 
Testosterone ameliorates the expression of inflammation factors, improves lipid profile 
in hypogonadal men [180], and inhibits vascular calcification [181]. Thus, unlike 
estrogens, and although there are many studies showing a preventive role of androgens 
on hypertrophic remodeling, the mechanisms underlying this protection have not been 
elucidated yet. Androgens have been studied to a lesser extent than estrogens and 
indeed there are some contradictory results regarding effect of androgens on vascular 
media thickening, as in some studies the effect was beneficial while in others it was 
detrimental [70, 182]. 
Regarding eutrophic remodeling, less evidence can be found on the beneficial effects of 
sex hormones. Some studies have shown increased arterial stiffening associated with 
low serum levels of female sex steroids [183], and they clearly demonstrated that sex 
hormones themselves were able to reverse this situation when serum levels were 
restored [184]. They also showed that androgens did not contribute to reduce arterial 
stiffening in males as compared to estrogens in females. Nevertheless, this study does 
not determine the specific nature of the remodeling, as they only measured arterial 
stiffness but not vessel diameters. Other authors have addressed the relationship 
between arterial remodeling, intimal calcification and arterial stiffness, showing that 
testosterone inhibits vascular calcification [181]. These data also point to the idea that 
sex hormones may provide vascular protection against pathologic vascular remodeling. 
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AIMS AND OUTLINE 
The main focus of this thesis was to investigate the role of endogenous male sex 
hormones on the two mechanisms controlling peripheral vascular resistances, which are 
vascular tone and vascular structure.  
Regarding vascular tone, the studies presented deal with the neural control of vascular 
tone, analyzing the role of β-adrenoceptors and the participation of some prostanoids. 
Previous studies have reported that orchidectomy in male rats decreases the 
vasoconstrictor response to NA, though vasoconstriction induced by EFS and neuronal 
NO release are not modified. Chapters 2 and 3 of this thesis investigate further the 
effect of androgens on the processes driving the contractile response to EFS. 
Specifically, Chapter 2 analyzes possible differences in the EFS-induced NA release 
between control and orchidectomized rats, and since NA and neuronal NO release can 
be modulated by β-adrenoceptors, and female sex hormones can influence β-
adrenoceptor function, the sensitivity and participation of β-adrenoceptors in NA and 
NO release in segments from both control and orchidectomized rats were also 
analyzed. As NA-release was found not to be modified by orchidectomy, the next study, 
described in Chapter 3, analyzed the participation of TXA2 in the vasoconstrictor 
response to EFS in both groups of rats, and the role of TXA2 on both the release and 
response to NA and NO. This study also describes an interaction between TXA2 PGI2 
and NO release in arteries from orchidectomized animals. 
Regarding vascular structure, previous studies have shown alterations in the structure 
of arteries from orchidectomized rats. Hence, the study presented in Chapter 4, aimed 
to determine the effect of sex hormones on vascular remodeling. It analyzes the 
possible preventive effect of testosterone on the inward remodeling induced by chronic 
vasoconstriction in small mesenteric vessels from male rats, as well as the role of TG2 
in this effect.  
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2 
Orchidectomy increases β-adrenoceptor  
activation-mediated neuronal nitric oxide and 
noradrenaline release in rat mesenteric artery.
 
 
J Blanco-Rivero, R Aras-López,  L del Campo, 
A Sagredo, G Balfagón, M Ferrer 
Neuroendocrinology 2006;84:378–385 
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ABSTRACT 
 
Background/Aims. A previous study has demonstrated that endogenous male sex 
hormones do not alter neuronal nitric oxide (NO) release in rat mesenteric artery. 
However, the regulatory role of endogenous male sex hormones on noradrenaline 
(NA) release in rat mesenteric artery is not known. The present study was designed 
to analyse whether endogenous male sex hormones influence the NA release 
induced by electrical field stimulation (EFS), as well as the possible modification in 
NA and neuronal NO release by presynaptic β-adrenoceptor activation.  
Methods. For this purpose, mesenteric artery from control and orchidectomized 
male Sprague-Dawley rats were used. Basal and EFS-induced neuronal NO and 
noradrenaline release, as well as the contractile effect induced by EFS, was 
measured. 
Results. Basal and EFS-induced neuronal NO and NA release were similar in 
arteries from control and orchidectomized rats. The β-adrenoceptor agonist 
clenbuterol did not modify EFS-induced neuronal NO and NA release in arteries from 
control rats. On the contrary, in arteries from orchidectomized animals, clenbuterol 
increased both neuronal NO and NA release, this increase was prevented by 
incubation with the β-adrenoceptor antagonist propranolol. However, the contractile 
response elicited by EFS was not modified by clenbuterol in either group of rats.  
Conclusions. These results show that orchidectomy does not alter the EFS-induced 
NA release. What is more, activation of presynaptic β-adrenoceptors does not modify 
EFS-induced NA and neuronal NO release in arteries from control rats although it 
increases the release of both neurotransmitters in arteries from orchidectomized rats. 
Despite these modifications, the EFS-induced contractile response is preserved in 
arteries from orchidectomized rats. 
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INTRODUCTION 
 
Vascular tone is regulated by several mechanisms in which, depending on the type 
of the vessel, innervation plays a more or less important role [1-3]. The perivascular 
sympathetic innervation of rat mesenteric arteries releases noradrenaline (NA) when 
electrically stimulated [4]. In its turn, the released NA can either induce a contractile 
response via α-adrenoceptor activation [5, 6] or it can activate β-adrenoceptors that 
relax the blood vessels [1]. It has also been demonstrated that electrical field 
stimulation (EFS) induces nitric oxide (NO) release from nitrergic nerves in rat 
mesenteric arteries [5-8], thus producing relaxation by stimulating soluble guanylate 
cyclase and increasing the intracellular levels of cGMP in the smooth muscle cells of 
the arterial wall [9, 10].  
The existence of β-adrenoceptors in different vascular wall cell types has been 
reported. Presynaptic β-adrenoceptors and their role in facilitating NA [11, 12] and 
neuronal NO [6, 7] release from adrenergic and nitrergic innervations, respectively, in 
rat mesenteric arteries have been demonstrated. Postsynaptic β-adrenoceptors 
induce a smooth muscle vasodilator response [1, 13] as well as endothelial NO 
release [14]. 
The role of male sex hormones in modulating vascular wall structure and function is 
the object of recent studies [8, 15]. For many years androgens have been associated 
with an increased risk of cardiovascular disease, but recent studies have reported 
that androgens have some protective effects in males [16-19] in which endothelial 
NO is involved. In this sense, we have described, in rat mesenteric artery, that 
orchidectomy did not modify endothelial NO release, while it decreased the response 
induced by acetylcholine [20]. Likewise, we have already studied the role of 
endogenous male sex hormones in the release of the vasodilator neurotransmitter 
NO, in the same artery, and we observed that this neuronal NO release was not 
modified by endogenous male sex hormones [8]. However, little information is 
available on the specific effect of endogenous male sex hormones in the release of 
the vasoconstrictor neurotransmitter NA in the peripheral nervous system. Studies on 
this issue, mostly performed in the central nervous system, have produced 
contradictory results; decreased [21], increased [22] and unmodified [23] NA release 
have been reported in orchidectomized animals. 
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In view of these observations, and taking into account female sex hormone 
modulation of postsynaptic β-adrenoceptor function in rat mesenteric arteries [13], it 
would be possible to speculate that male sex hormones could influence presynaptic 
β-adrenoceptor function, thereby modulating NA and neuronal NO release through β-
adrenoceptor activation. 
Therefore, the present work analyses whether endogenous male sex hormones 
influence the NA release induced by EFS in rat mesenteric artery, as well as the 
possible modification in the NA and neuronal NO release modulated by presynaptic 
β-adrenoceptors activation. 
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MATERIALS AND METHODS 
 
Animal housing and protocols 
Male Sprague-Dawley rats (6 months old) were used. These were divided into two 
groups: control and orchidectomized rats. All animals were housed in the Animal 
Facility of the Universidad Autónoma de Madrid (Registration number EX-021U) in 
accordance with directives 609/86 CEE and R.D. 233/88 of the Ministerio de 
Agricultura, Pesca y Alimentación of Spain. Male sex hormone deprivation was 
induced by gonadectomy at 7 weeks of age, and 4 months later the animals were 
sacrificed. The observation of seminal vesicle atrophy confirmed successful surgery. 
Rats were sacrificed by CO2 inhalation; the first branch of the mesenteric artery was 
carefully dissected out, cleaned of connective tissue and placed in Krebs-Henseleit 
solution (KHS, in mM: NaCl 115, CaCl2 2.5, KCl 4.6, KH2PO4 1.2, MgSO4.7H2O 1.2, 
NaHCO3 25, glucose 11.1, Na2 EDTA 0.03) at 4 ºC.  The investigation conforms to 
the Guide for the Care and Use of Laboratory Animals published by the USA 
National Institutes of Health (NIH publication No. 85.23 revised 1985). 
 
Tritium release experiments 
Segments of rat mesenteric arteries of 4 mm in length were set up in a nylon net and 
immersed for 30 min in 10 ml of KHS at 37 ºC continuously gassed with 95% O2 -  
5% CO2 (stabilisation period). Thereafter, the segments were incubated for 60 min in 
1 ml of bubbled KHS at 37 ºC containing (+)-[3H]NA (0.33 µM, 10 µCi/ml, specific 
activity 10 Ci/mmol). The arteries were then transferred to a superfusion chamber 
with two parallel platinum electrodes, 0.5 cm apart, connected to a stimulator (Grass, 
model S44) for EFS. The arteries were superfused at a rate of 2ml/min with 
oxygenated KHS at 37 ºC for 100 min, during which time the steady-state level of 
basal tritium efflux was reached. At this time, two samples were collected with an 
interval of 30 s to determine basal tritium release. Then, an electrical stimulation 
period of 60 s (S1; 200 mA, 0.3 ms, 4 Hz) was applied to the arteries while the 
superfusate was being collected at 30 s intervals. After the S1 samples, six more 
samples were also collected, at 30 s intervals, to determine the recovery basal level 
of the tritium efflux.  
At 45 min after the S1 period, a second stimulation period (S2) of equal 
characteristics was performed. In some set of experiments, either clenbuterol or 
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propranolol, the respective β-adrenoceptor agonist or antagonist used to interfere 
with tritium release, were administered 30 min before S2. 
Ready-Protein solution (Beckman) was then added to the vials and the radioactivity 
was measured in a scintillation counter (Beckman LS 5000 TD). Cocaine (10 µM) 
and normetanephrine (10 µM) were added to the superfusion fluid after the 
incubation period, and maintained throughout the experiment to block neuronal and 
extraneuronal uptake of NA respectively. 
The stimulation-induced 3H release was calculated by subtracting basal tritium 
release from that evoked by EFS. Thereafter, the ratios of the net tritium release 
between S2/S1 were calculated to eliminate differences among arteries. The actions 
of the drugs on the evoked release were expressed as their effects on these ratios. 
The amount of radioactivity released was expressed in dpm/mg. 
 
Nitric Oxide release 
Endothelium-denuded mesenteric arteries from control and orchidectomized rats 
were subjected to a resting tension of 0.5 g as indicated for the reactivity 
experiments. After an equilibration period of 60 min, arteries were incubated with the 
fluorescent probe 4,5-diaminofluorescein (DAF-2, 0.5 µM) for 45 min. Then, the 
medium was collected to measure basal NO release. Once the organ bath was 
refilled, cumulative EFS periods of 30 s at 1, 2, 4, 8 and 16 Hz at 1 min intervals 
were applied. The fluorescence of the medium was measured at room temperature 
using a spectrofluorimeter (LS50 Perkin Elmer instruments, FL WINLAB Software) 
with excitation wavelength set at 495 nm and emission wavelength at 515 nm. 
Validation of this method has been studied by comparing the results obtained with 
DAF with those obtained by nitrites measurement (Martín et al., 2005). 
The interference of clenbuterol (1 µM), propranolol (1 µM) or clenbuterol plus 
propranolol on NO release was studied by incubating the arteries with these drugs 30 
min before collecting medium to determine basal NO release, or 30 min prior to the 
EFS application for determination of EFS-induced NO release.  
The EFS-induced NO release was calculated by subtracting basal NO release from 
that evoked by EFS. Also, blank measures were collected in the same way from 
segment-free medium in order to subtract background emission. Some assays were 
performed in the presence of the constitutive NOS inhibitor, Nω-nitro-L-arginine 
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methyl ester (L-NAME, 0.1 mM) to ensure the specificity of the method. The amount 
of NO released was expressed as arbitrary units/mg tissue. 
 
Vascular reactivity 
The method used for isometric tension recording has been described in full 
elsewhere [24]. Briefly, two parallel stainless steel pins were introduced through the 
lumen of the vascular segment: one was fixed to the bath wall, and the other 
connected to a force transducer (Grass FTO3C; Quincy, Mass., USA); this was 
connected in turn to a model 7D Grass polygraph. For EFS experiments, segments 
were mounted between two platinum electrodes 0.5 cm apart and connected to a 
stimulator (Grass, model S44) modified to supply adequate current strength. 
Segments were suspended in an organ bath containing 5 ml of KHS at 37oC 
continuously bubbled with a 95% O2-5%CO2 mixture (pH of 7.4). Experiments were 
performed in endothelium-denuded segments to eliminate the main source of 
vasoactive substances, including endothelial NO. This avoided possible actions by 
different drugs on endothelial cells that could lead to misinterpretation of results. 
Endothelium was removed by gently rubbing the luminal surface of the segments 
with a thin wooden stick. The segments were subjected to a tension of 0.5 g which 
was readjusted every 15 min during a 90 min equilibration period before drug 
administration. After this, the vessels were exposed to 75 mM KCl to check their 
functional integrity. Endothelium removal did not alter the contractions elicited by 75 
mM KCl. After a washout period, the absence of vascular endothelium was tested by 
the inability of 10 µM acetylcholine (ACh) to relax segments precontracted with 1 µM 
noradrenaline (NA).  
Frequency-response curves to EFS (1, 2, 4, 8 and 16 Hz) and concentration-
response curves to NA (10 nM-10 µM) were performed. The parameters used for 
EFS were 200 mA, 0.3 ms, 1-16 Hz, for 30 s with an interval of 1 min between each 
stimulus, the time required to recover basal tone. A washout period of at least 1 h 
was necessary to avoid desensitisation between consecutive curves. Three 
successive frequency-response curves separated by 1h intervals produced similar 
contractile response.  
To determine the effect of clenbuterol on the response induced by EFS, this drug 
was added to the bath 30 min before the second frequency-response stimulation. 
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The ability of clenbuterol to induce relaxation was analysed in NA-precontracted 
segments from both groups. 
The possible effect of clenbuterol on basal tone and on the vasodilator effect of 
sodium nitroprusside (SNP) was also examined in segments from both rat groups. 
Drugs  
L-NA hydrochloride, ACh chloride, L-NAME hydrochloride, sodium nitroprusside, 
clenbuterol hydrochloride, propranolol hydrochloride, DAF-2 (Sigma-Aldrich; Spain); 
and (+)-[3H]NA hydrochloride from New England Nuclear, Boston, MA, USA. Stock 
solutions (10 mM) of drugs were made in distilled water, except for NA which was 
dissolved in a NaCl (0.9%)-ascorbic acid (0.01% w/v) solution. These solutions were 
kept at –20 ºC and appropriate dilutions were made in KHS on the day of the 
experiment. 
Data Analysis 
The responses elicited by EFS, KCl, or NA were expressed in mg for comparison 
between control and orchidectomized male rats.  The relaxation induced by SNP or 
clenbuterol was expressed as a percentage of the initial contraction elicited by NA. 
Results are given as mean ± SEM. Statistical analysis was done by comparing the 
curve obtained in the presence of the different substances with the previous or 
control curve by means of repeated-measure analysis of variance (ANOVA). For the 
experiments of NO and NA release, the statistical analysis was done using a 
Student’s t test for unpaired experiments. A p value of less than 0.05 was considered 
significant. 
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RESULTS 
 
Tritium release experiments 
Basal tritium release was similar in arteries from control and orchidectomized rats 
(control, 95 + 4.8 dpm/mg; orchidectomized 79.8 + 5.2 dpm/mg, n= 14; p > 0.05). 
Electrical stimulation induced tritium release; the release obtained in S2 (control, 
333.5 +31.05 dpm/mg; orchidectomized 353.4 + 20.14 dpm/mg, n = 4; p > 0.05) was 
similar to that found in S1 (control, 370.8 + 28.7 dpm/mg; orchidectomized, 338.1 + 
18.9 dpm/mg, n = 4; p > 0.05). The S2/S1 ratio for segments from control animals 
was not significantly different from the one in orchidectomized rats (control, 0.89 + 
0.1; orchidectomized, 1.04 + 0.09; p > 0.05). Tritium release was markedly reduced 
by 0.1 µM tetrodotoxin (S2/S1, 0.04 + 0.01; n=4, p < 0.001) in both groups. 
In segments from control rats, neither clenbuterol (1 µM, the β-adrenoceptor agonist) 
nor propranolol (1 µM, the β-adrenocpetor antagonist) modified the stimulated tritium 
release (Fig. 1a). In segments from orchidectomized rats, the presence of 
clenbuterol increased the tritium release induced by EFS, and this increase was 
blocked by prior incubation with propranolol (Fig. 1b) 
Basal tritium release was not affected by clenbuterol or propranolol preincubation in 
control or orchidectomized rats (data not shown). 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1. Effect of clenbuterol (Clen.) or propranolol (Prop.) on the electrically stimulated tritium release in 
mesenteric artery segments from control rats. Effect of Clen., Prop. or Prop. + Clen. on the electrically 
stimulated tritium release in mesenteric artery segments from orchidectomized rats. Results (means + 
SEM.) are expressed as the ratio S2/S1. n = Number of animals. * p< 0.05 vs control (C); + p<0.05 vs 
Clen. 
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Nitric Oxide release 
Basal NO release was similar in mesenteric arteries from both control and 
orchidectomized rats (ANOVA, p > 0.05). EFS induced a similar increase of NO 
release in arteries from both control and orchidectomized rats (ANOVA, p > 0.05). In 
segments from control rats, preincubation with either clenbuterol or propranolol did 
not modify the basal or the stimulated NO release (Fig. 2a). In contrast, in segments 
from orchidectomized rats, preincubation with clenbuterol enhanced basal and 
electrically-stimulated NO release (Fig. 2b). The facilitatory effect induced by 
clenbuterol was not reversed by preincubation with propranolol (1 µM), but, when the 
propranolol concentration was increased to 10 µM, the facilitatory effect was blocked 
(Fig. 2b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 2.  Effect of clenbuterol (Clen.) or propranolol (Prop.) on the basal- and EFS-induced NO release 
in mesenteric artery segments from control rats. Effect of Clen., Prop. or Prop. + Clen. on the basal- 
and EFS-induced NO release in mesenteric artery segments from orchidectomized rats. Results 
(means + SEM.) are expressed as arbitrary units. n = Number of animals. * p< 0.05 vs the respective 
basal NO release; + p<0.05 vs the basal- and EFS-induced NO release in absence of any drug (C). 
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reduced by phentolamine (1 µM), the antagonist of α-adrenoceptors, in segments 
from both groups, as we have previously reported [8].  
In segments from control and orchidectomized rats, the presence of 1 µM clenbuterol 
did not modify the contractile response to EFS (Fig. 3a, b).  
The contractile tone obtained with NA was 1002 + 72 mg in arteries from control rats 
and 748 + 67 mg in arteries from orchidectomized rats, n= 7-10. In these 
precontracted segments, clenbuterol (10 nM-1 µM) induced a very slight 
concentration-dependent relaxation, and this relaxation was similar in segments from 
both control and orchidectomized rats (1 µM induced 7.3 + 2.2 and 6.5 + 2.4 % of 
inhibition of the previous tone with NA, respectively). 
Clenbuterol preincubation did not modify the vasodilator response induced by SNP 
(0.1 nM- 10 µM) in arteries precontracted with NA from either group (Fig. 4). 
None of these drugs affected the basal tone or the concentration-dependent 
contraction curves to NA (data not shown). 
 
 
 
 
 
 
 
 
 
Fig. 3. Effect of clenbuterol (Clen) on the frequency-response curve in mesenteric artery segments 
from control and orchidectomized rats. Results (means + SEM.) are expressed as a percentage of 
tone induced by 75 mM KCl. n = Number of animals. 
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Fig. 4. Effect of clenbuterol (Clen) on the concentration-response curve to sodium nitroprusside (SNP) 
in mesenteric artery segments from control and orchidectomized rats. Results (means + SEM.) are 
expressed as a percentage of a previous tone with noradrenaline. n = Number of animals.
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DISCUSSION 
 
The results of the present study demonstrate that endogenous male sex hormones 
are involved in the regulation of the presynaptic β-adrenoceptor function in rat 
mesenteric artery. In fact, activation of presynaptic β -adrenoceptors facilitates NA 
and neuronal NO release in mesenteric arteries from orchidectomized rats, but not in 
arteries from control rats. In spite the changes produced in arteries from 
orchidectomized rats, the contractile response induced by EFS remains unaltered. 
The balance between opposing vasoconstrictor and vasodilator forces is one of 
several factors that control vascular tone [6, 25]. Rat mesenteric arteries possess 
rich sympathetic [4], sensory motor [3] and nitrergic innervations [7, 8], which 
modulate vasomotor tone. In a previous work we have demonstrated that EFS 
induced contractile response in endothelium-denuded mesenteric segments from 
control and orchidectomized male rats; these responses appear to be mediated by 
NA release from adrenergic nerve terminals and the subsequent activation of α-
adrenoceptors in both experimental hormonal conditions, as has been described in 
other rat strains [5, 26]. We also demonstrated the involvement of neuronal NO in 
the EFS-induced response, and quantification of the NO release showed that EFS 
induced similar releases of neuronal NO in both control and orchidectomized rats [8]. 
Our results indicate the involvement of neuronal NO in the EFS-induced response in 
rat mesenteric artery, but they do not determine the anatomical identity of the 
nitrergic perivascular nerves involved in NO release. In this sense, a recent report 
shows that perivascular capsaicin-sensitive nerves release NO [27], although we 
observed that sensory innervation was not involved in the vasomotor response to 
EFS in segments from both control and orchidectomized rats [8].  
The fact that the contractile response to exogenous NA was diminished in arteries 
from orchidectomized rats while the EFS response was similar in both groups of rats, 
suggested that EFS could modulate neurotransmitter release in mesenteric arteries 
from orchidectomized rats. Studies on the modulatory effect of male sex hormones in 
NA release in the central nervous system have contradictory results: increase [22, 
28], decrease [21, 29] and no modification [23, 30]. However, the issue of male sex 
hormones modulating NA release had not been studied in the peripheral nervous 
system. Therefore, we analysed the influence of endogenous male sex hormones on 
NA release by studying the possible changes in the tritium overflow induced by EFS 
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in [3H]-NA preincubated segments from both rat groups. The results show that 
orchidectomy did not modify the tritium overflow induced by EFS, suggesting that 
other vasoconstrictor factors were released when the artery was electrically 
stimulated. 
Nevertheless, modulation of NA [12] and neuronal NO [7] release by presynaptic β-
adrenoceptor has been reported, although these effects have not been observed in 
all tissues [6, 11]. Additionally, we know that β-adrenoceptor function can be altered 
in physiopathological conditions, such as aging or hypertension, in endothelial cells 
[31], smooth muscle cells [32, 33] and presynaptic endings [34, 35]. Since 
modulation of β-adrenoceptor function by female sex hormones has been described 
[13], it is possible to speculate that male sex hormones could also modulate 
presynaptic β-adrenoceptor function. To investigate this possibility, we studied the 
effect of the β-adrenoceptor agonist clenbuterol on noradrenergic neurotransmission 
by assessing its capacity to modulate the tritium overflow induced by EFS. 
Clenbuterol did not significantly alter the EFS-induced overflow in segments from 
control rats, confirming that activation of presynaptic β-adrenoceptors does not 
influence noradrenergic transmission in mesenteric arteries from control animals, as 
shown previously [6, 36]. However, the activation of presynaptic β-adrenoceptors 
increased NA release in arteries from orchidectomized rats. The fact that propranolol 
prevented the facilitatory effect induced by clenbuterol indicates that this effect is 
mediated by β-adrenoceptor activation, and this activation could result in an 
increased local peripheral resistance.  
Since functional studies have shown that neuronal NO release is modulated by 
presynaptic β-adrenoceptors in different rat strains [6, 7], we analysed the effect of β-
adrenoceptor activation on neuronal NO release by measuring the fluorescence 
emitted by DAF-2. We observed that, in segments from control rats, clenbuterol and 
propranolol both failed to modify the basal and EFS-induced neuronal NO release. 
On the contrary, clenbuterol increased both the basal and the electrically-stimulated 
NO release in arteries from orchidectomized rats. The fact that the β-adrenoceptor 
antagonist, propranolol, prevented the clenbuterol-induced NO release indicates that 
the facilitatory effect is mediated by β-adrenoceptor activation. It is important to note 
that to reverse the facilitatory effect on neuronal NO release induced by clenbuterol, 
it was necessary to use a higher concentration of propranolol than the concentration 
needed to reverse its effect on NA release. This fact could also indicate that the 
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presynaptic β-adrenoceptors modulating NO release seem to be more numerous 
and/or have a greater affinity for clenbuterol than those modulating NA release. 
However, what is of importance is that the activation of β-adrenoceptors increased 
EFS-induced neurogenic NA and NO only in orchidectomized rats.  
The next step was to investigate the functional role of β-adrenoceptor activation in 
the arterial vasomotor response induced by EFS. We observed that the EFS-induced 
contractile response was not modified by clenbuterol in arteries from control or 
orchidectomized rats. These results agree with the fact that clenbuterol does not 
modify either the neuronal NO or NA release in mesenteric arteries from control 
animals. This result differs from that presented by Marín and Balfagón [7], where 
clenbuterol inhibited the contraction induced by EFS. This apparent discrepancy 
could be due to the different rat strains used in the two studies. However, although 
the net effect of clenbuterol on EFS-induce contraction in arteries from 
orchidectomized rats was similar to that produced in arteries from control rats, the 
mechanisms involved are different. In arteries from orchidectomized rats, the non 
modification observed in the presence of clenbuterol is due, at least in part, to an 
increased release of the two opposing vasoconstrictor and vasodilator 
neurotransmitters: NA and NO respectively, as was demonstrated with the NA and 
NO release experiments. A possible interaction between β-adrenoceptor activation 
and the vascular effect of neuronal NO was ruled out since the vasodilator action of 
sodium nitroprusside was not modified by preincubation with clenbuterol.  
Having described a modulatory action on postsynaptic α-adrenoceptors by 
endogenous male sex hormones [37], we further investigated the possible effect of 
orchidectomy on postsynaptic β-adrenoceptor function by performing concentration-
dependent relaxation curves to clenbuterol. We observed that clenbuterol induced a 
very modest relaxation in segments precontracted with NA, and that this relaxation 
was similar in arteries from both rat groups; this suggests that orchidectomy does not 
affect the function of postsynaptic β-adrenoceptors. On the other hand, the possible 
interaction between α- and β-adrenoceptors was studied, because increases [38] 
and decreases [39] in α-adrenoceptor-mediated contraction have both been 
described in the presence of the β-agonists. We  observed that preincubation with 
clenbuterol did not modify the contraction elicited by exogenous NA in arteries from 
either control or orchidectomized rats, indicating that activation of β-adrenoceptors 
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had no effect on the response induced by α-adrenoceptor activation in arteries from 
either rat groups.  
In conclusion, our results show that orchidectomy does not alter EFS-induced NA 
release. Additionally, activation of presynaptic β-adrenoceptors does not modify NA 
and neuronal NO release in mesenteric arteries from control rats. However, in 
arteries from orchidectomized rats, presynaptic β-adrenoceptor activation increases 
the EFS-induced NA release.  This increase in available NA in the absence of male 
hormones would intensify the vasomotor and trophic action of NA on the vessel wall 
[40, 41] and thereby, probably affect cardiovascular function adversely.  In addition, 
β-adrenoceptor activation also increases neuronal NO release in these 
orchidectomized rats, in what may be an attempt to compensate for the vascular 
actions produced by the NA.  
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3 
Orchidectomy increases the formation of  
non-endothelial thromboxane A2 and modulates its 
role in the electrical field stimulation-induced 
response in rat mesenteric artery. 
 
L del Campo, A Sagredo, R Aras-López,  
G Balfagón,  M Ferrer 
Journal of Endocrinology 2008;197: 371–379 
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ABSTRACT 
 
The aim of the present study was to analyze whether endogenous male sex hormones 
influence the release of thromboxane TXA2 and its role in the electrical field stimulation 
(EFS)-induced response, as well as the mechanism involved. For this purpose, 
endothelial-denuded mesenteric arteries from control and orchidectomized male 
Sprague-Dawley rats were used to measure TXA2 release; EFS-induced response, 
nitric oxide (NO), noradrenaline (NA) and prostaglandin (PG) I2 release were also 
measured in the presence of the TXA2 synthesis inhibitor furegrelate. Orchidectomy 
increased basal and EFS-induced TXA2 release. Furegrelate decreased the EFS-
induced contraction in arteries from control rats, but did not modify it in arteries from 
orchidectomized rats. The EFS-induced neuronal NO release and vasodilator response 
was increased by furegrelate in arteries from control rats, but were not modified in 
arteries from orchidectomized rats. Furegrelate did not modify the EFS-induced NA 
release or vasoconstrictor response in arteries from either control or orchidectomized 
rats. The EFS-induced PGI2 release was not modified by furegrelate in arteries from 
control rats, but was increased in arteries from orchidectomized rats. The results of the 
present study show that endogenous male sex hormone deprivation: (i) increases non-
endothelial TXA2 release, and (ii) regulates the effect of endogenous TXA2 on the EFS-
induced response through different mechanisms that, at the least, involve the NO and 
PGI2 systems. In arteries from control rats, inhibition of TXA2 formation decreases the 
EFS-induced response by increasing neuronal NO release. In arteries from 
orchidectomized rats, the EFS-induced response is unaltered after the inhibition of TXA2 
formation, by increasing PGI2 release.  
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INTRODUCTION 
 
Clinical and epidemiological studies indicate the existence of gender differences in the 
incidence of cardiovascular disease and have established the existence of vascular 
protective effects of endogenous estrogens (Teede 2007). On their part, androgens 
have generally been associated with impaired vascular reactivity; nevertheless, recent 
studies have reported beneficial properties of androgens in male vascular function 
(Blanco-Rivero et al. 2006a,b) similar to the effects of estrogens in women 
(Alexandersen et al. 1999, Ng 2007). In addition, low levels of testosterone have been 
reported in patients with hypertension (Phillips et al. 1993), atherosclerosis 
(Alexandersen et al. 1996) and coronary disease (Wranicz et al. 2005). 
Vascular tone is regulated by several mechanisms in which, depending on the type of 
the vessel, innervation plays a more or less important role. This regulation involves the 
adrenergic, cholinergic, nitrergic, peptidergic and/or sensory innervations (Vanhoutte et 
al. 1981; Marco et al. 1985; Kawasaki et al, 1988), that are specific to the vascular bed 
under consideration. Nitric oxide (NO) is an important neurotransmitter in both the 
central (Bredt et al. 1992) and the peripheral (Marín & Balfagón 1998) nervous systems. 
Electrical field estimulation (EFS) has been shown to induce NO release from nitrergic 
nerves in rat mesenteric arteries (Ferrer et al. 2000, Ferrer & Balfagón 2001, Marín & 
Balfagón 1998, del Carmen Martín et al. 2005), thus producing relaxation by stimulating 
soluble guanylate cyclase and increasing the intracellular levels of cGMP in the smooth 
muscle cells of the arterial wall (Holtzmann 1982, Ignarro & Kadowitz 1985). Sex 
hormones have been described to modulate the release and/or function of the neuronal 
NO in male (del Carmen Martín et al. 2005) and female (Minoves et al. 2002) rat 
mesenteric artery.  
Vascular tone is also regulated by prostanoids originated by the arachidonic acid 
metabolism through the cyclooxygenase (COX) pathway (Henrion et al. 1997, Félétou & 
Vanhoutte 2006, Blanco-Rivero et al. 2005). One of the most studied prostanoids is 
thormboxane A2 (TXA2), which has been implicated as a mediator in diseases such as 
myocardial infarction, hypertension and stroke (FitzGerald et al. 1987, Narumiya et al. 
1999). We previously reported that, in mesenteric artery from comparable rats, 
endogenous male sex hormones modulate endothelial TXA2 production, whether in 
basal conditions or after stimulation with either clonidine (Blanco-Rivero et al. 2006a) or 
acetylcholine (Blanco-Rivero et al., 2007), without modifying the TXA2 vasoconstrictor 
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effect. Additionally, we have also shown that endogenous male sex hormones regulate 
the functional involvement of endogenous TXA2 in vascular responses of aorta 
(Martorell et al. 2008) and mesenteric artery (Blanco-Rivero et al. 2006a, Blanco-Rivero 
et al. 2007). 
On the other hand, while NO has been reported to modulate the prostanoid system 
(Salvemini et al. 1996, Laemmel et al. 2003), there have been few reports on the action 
of prostanoids on the NO system (Ferrer et al. 2004, Mollace et al. 2005). Moreover, 
regarding the specific action of TXA2 on the NO system, a decrease in inducible 
(Yamada et al. 2003) as well as endothelial (Miyamoto et al. 2007) NO release has 
been reported. However details about the action of TXA2 on neuronal NO release in 
vascular tissue remain unknown. 
In light of these considerations, the present study was designed to investigate whether 
endogenous male sex hormones influence the release of TXA2 and the role of the latter 
in the electrical field stimulation (EFS)-induced response, as well as the mechanism 
involved in this response.    
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MATERIALS AND METHODS 
 
Animal housing and protocols 
Male Sprague-Dawley rats (6 months old) were used. Animals were housed in the 
Animal Facility of the Universidad Autónoma de Madrid (Registration number EX-021U) 
in accordance with directives 609/86 CEE and R.D. 233/88 of the Ministerio de 
Agricultura, Pesca y Alimentación of Spain. Deprivation of male sex hormones was 
induced by gonadectomy at 7 weeks of age, and 4 months later the animals were 
sacrificed. The observation of seminal vesicles atrophy confirmed successful surgery. 
Rats were weighed and sacrificed by CO2 inhalation; the first branch of the mesenteric 
artery was carefully dissected out, cleaned of connective tissue and placed in Krebs-
Henseleit solution (KHS, in mM: NaCl 115, CaCl2 2.5, KCl 4.6, KH2PO4 1.2, 
MgSO4.7H2O 1.2, NaHCO3 25, glucose 11.1, Na2 EDTA 0.03) at 4º C. Endothelium 
was removed to eliminate the main source of vasoactive substances, including NO. This 
avoided possible actions on endothelial cells by different drugs that could lead to 
misinterpretation of results. Endothelium was removed by gently rubbing the luminal 
surface of the segments with a thin wooden stick. The investigation conforms to the 
Guide for the Care and Use of Laboratory Animals published by the USA National 
Institutes of Health (NIH publication No. 85.23 revised 1985). 
 
Thromboxane A2, noradrenaline and prostaglandin I2  (PGI2) release 
The production of TXA2 and PGI2 in vivo are typically monitored by measuring their 
stable metabolites TXB2 and 6-keto-PGF1α,, respectively, using a TXB2 or a 6-keto-
PGF1α EIA kit (Cayman Chemical). Noradrenaline was measured using Noradrenaline 
Research EIA (Labor Diagnostika Nord). 
Endothelial-denuded rat mesenteric segments were preincubated for  30 min in 5 ml 
KHS at 37 ºC, continuously gassed with a 95 % O2-5% CO2 mixture (stabilization 
period). After several 10 min washout periods in a bath containing 400 µl KHS, the 
medium was collected to measure basal release. Once the chamber was refilled 
cumulative EFS periods of 30 s at 1, 2, 4, 8 and 16 Hz at 1 min intervals were applied, 
and the medium was collected to measure EFS-induced release. Each assay was made 
following the manufacturer’s instructions. Results were expressed as pg / mL.mg tissue 
for TXA2 and PGI2 release and as ng / mL.mg tissue for NA release. 
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Vascular reactivity 
The method used for isometric tension recording has been described in full elsewhere 
(Nielsen & Owman 1971). Briefly, two parallel stainless steel pins were introduced 
through the lumen of the vascular segment: one was fixed to the bath wall, and the 
other connected to a force transducer (Grass FTO3C; Quincy, Mass., USA); this was 
connected in turn to a model 7D Grass polygraph. For EFS experiments, segments 
were mounted between two platinum electrodes 0.5 cm apart and connected to a 
stimulator (Grass, model S44) modified to supply appropiate current strength. Segments 
were suspended in an organ bath containing 5 ml KHS at 37oC continuously bubbled 
with a 95% O2-5%CO2 mixture (pH of 7.4). The segments were subjected to a tension 
of 0.5 g which was readjusted every 15 min during a 90 min equilibration period before 
drug administration. After this, the vessels were exposed to 75 mM KCl to check their 
functional integrity. Endothelium removal did not alter the contractions elicited by 75 mM 
KCl. After a washout period, the absence of vascular endothelium was tested by the 
inability of 10 µM acetylcholine (ACh) to relax segments precontracted with 1 µM 
noradrenaline (NA).  
Frequency-response curves to EFS (1, 2, 4, 8 and 16 Hz) and concentration-response 
curves to NA (10 nM-10 µM) were performed. The parameters used for EFS were 200 
mA, 0.3 ms, 1-16 Hz, for 30 s with an interval of 1 min between each stimulus, the time 
required to recover basal tone. A washout period of at least 1 h was necessary to avoid 
desensitization between consecutive curves. Three successive frequency-response 
curves separated by 1h intervals produced similar contractile responses.  
To determine the effect of endogenous TXA2 on the response induced by EFS the TXA2 
synthase inhibitor, furegrelate (1 µM), was added to the bath 30 min before the second 
frequency-response curve. 
To determine the possible effect of endogenous TXA2 on the NA-induced 
vasoconstrictor response furegrelate was added to the bath 30 min before performing 
the NA concentration response curve. The possible effect of furegrelate on the 
vasodilator effect of NO was also analyzed by performing concentration-response 
curves to the NO donor sodium nitroprusside (SNP) in 30 min furegrelate preincubated 
arteries. 
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Nitric Oxide release 
Endothelium-denuded mesenteric arteries from control and orchidectomized rats were 
subjected to a resting tension of 0.5 g as indicated for the reactivity experiments. After 
an equilibration period of 60 min, arteries were incubated with the fluorescent probe 4,5-
diaminofluorescein (DAF-2, 0.5 µM) for 45 min. Then the medium was collected to 
measure basal NO release. Once the organ bath was refilled, cumulative EFS periods 
of 30 s at 1, 2, 4, 8 and 16 Hz at 1 min intervals were applied. The fluorescence of the 
medium was measured at room temperature using a spectrofluorimeter (LS50 Perkin 
Elmer instruments, FL WINLAB Software) with excitation wavelength set at 495 nm and 
emission wavelength at 515 nm. This method has been validated by comparing the 
results obtained with DAF with those obtained by nitrites measurement (del Carmen 
Martín et al. 2005). 
The interference of endogenous TXA2 on NO release was studied by incubating the 
arteries with the TXA2 synthase inhibitor furegrelate (1 µM) 30 min before collecting 
medium. 
Each data was calculated by subtracting the blank measures from the corresponding 
NO release obtained. Blank measures were collected in the same way from segment-
free medium in order to subtract background emission. The specificity of the method 
has already been demonstrated (del Carmen Martín et al. 2005, Blanco-Rivero et al. 
2006c). The amount of NO released was expressed as arbitrary units/mg tissue. 
 
Drugs 
L-NA hydrochloride, ACh chloride, L-NAME hydrochloride, sodium nitroprusside, DAF-2 
(Sigma-Aldrich; Spain); furegrelate (Cayman chemical, Europe). Stock solutions (10 
mM) of drugs were made in distilled water, except for NA which was dissolved in a NaCl 
(0.9%)-ascorbic acid (0.01% w/v) solution. These solutions were kept at -20 ºC and 
appropriate dilutions were made in KHS on the day of the experiment. 
 
Data Analysis 
The responses elicited by EFS or NA were expressed as a percentage of the 
contraction induced by 75 mM KCl.  The relaxation induced by SNP was expressed as a 
percentage of the initial contraction elicited by 1µM NA. Results are given as mean ± 
SEM. Statistical analysis was done by comparing the curve obtained in the presence of 
the different substances with the previous or control curve by means of repeated-
  78 
measure analysis of variance (ANOVA). For the experiments on TXA2, NO, NA and 
PGI2 release, the statistical analysis was done using a Student’s t test for unpaired 
experiments. A p value of less than 0.05 was considered significant. 
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RESULTS 
Body weight 
Orchidectomy slightly decreased rat body weight (control, 469.7 + 8.4 g; 
orchidectomized, 428 + 5.4 g; n= 10; p < 0.05), but this did not affect the size of 
mesenteric artery. 
Thromboxane A2 release 
Orchidectomy increased basal TXA2 release. The EFS-induced TXA2 release was 
greater in arteries from orchidectomized than control male rats (Fig. 1). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Basal and EFS-induced thromboxane A2 (TXA2) release in mesenteric 
denuded segments from control (A) and orchidectomized (B) rats. Results (mean + 
S.E.M) are expressed as pg/mL.mg tissue. Number of animals is indicated in 
parenthesis. *P<0.05 compared with basal TXA2 release. +P<0.05 compared with the 
respective control. 
 
Vascular reactivity 
Preincubation with the TXA2 synthase inhibitor furegrelate (1 µM) did not modify basal 
tone in arteries from either rat group; furegrelate decreased the EFS-induced 
contraction in arteries from control male rats (Fig. 2a), but did not modify it in arteries 
from orchidectomized rats (Fig. 2b). 
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Preincubation with furegrelate did not modify the NA-induced contraction in arteries 
from control (Fig. 3a) or orchidectomized rats (Fig. 3b). 
Preincubation with furegrelate increased the SNP-induced relaxation in arteries from 
control male rats (Fig.4a), but did not affect that induced in arteries from 
orchidectomized rats (Fig.4b). 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.  Effect of furegrelate on the frequency–response curve in mesenteric artery 
segments from control (A) and orchidectomized (B) rats. Results (mean + S.E.M) are 
expressed as a percentage of the tone induced by 75 mM KCl. n  = number of animals. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. Effect of furegrelate on the concentration-response curves to noradrenaline in 
mesenteric artery segments from control (A) and orchidectomized (B) rats. Results 
(mean + S.E.M.) are as a percentage of the tone induced by 75 mM KCl.  Number of 
animals is indicated in parenthesis. 
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Figure 4. Effect of furegrelate on the concentration-dependent curves to sodium 
nitroprusside in mesenteric artery segments from control (A) and orchidectomized (B) 
rats. Results (mean + S.E.M.) are expressed as a percentage of inhibition of contraction 
induced by 1 µM NA. Number of animals is indicated in parenthesis. 
 
Nitric Oxide release 
Basal and EFS-induced NO release was similar in mesenteric arteries from both control 
and orchidectomized male rats (ANOVA, p > 0.05). In segments from control male rats, 
preincubation with the TXA2 synthase inhibitor furegrelate did not modify the basal NO 
release, but did increase EFS-induced NO release (Fig. 5a). In contrast, in segments 
from orchidectomized rats, preincubation with furegrelate did not affect basal or EFS-
induced NO release (Fig. 5b); similar results were obtained when the furegrelate 
concentration was increased to 10 µM (Fig. 5b). 
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Figure 5. Effect of furegrelate (Fure.) on the basal and EFS-induced NO release in mesenteric denuded 
segments from control (A) and orchidectomized (B) rats. Results (means + S.E.M) are expressed as 
arbitrary units/mg tissue. Number of animals is indicated in parenthesis. * P<0.05 compared with basal 
TXA2 release. + P<0.05 compared with the respective control. 
 
Noradrenaline release 
Basal and EFS-induced NA release was similar in mesenteric arteries from both control 
and orchidectomized male rats (ANOVA, p > 0.05), as already reported using the tritium 
release method for measuring NA release (Blanco-Rivero et al. 2006c). The presence of 
furegrelate did not modify either the basal or the EFS-induced NA release in arteries 
from control (Fig. 6a) or orchidectomized (Fig. 6b) rats. 
 
 
 
 
 
 
 
 
Figure 6. Effect of furegrelate on the basal and EFS-induced noradrenaline (NA) release in mesenteric 
denuded segments from control (A) and orchidectomized (B) rats. Results (means + S.E.M) are 
expressed as ng /mL.mg tissue. Number of animals is indicated in parenthesis. * P<0.05 compared with 
basal NA release. + P<0.05 compared with the respective control. 
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PGI2 release 
Basal and EFS-induced PGI2 release was similar in mesenteric arteries from both 
control and orchidectomized male rats (ANOVA, p > 0.05). Furegrelate did not modify 
this release in arteries from control rats (Fig. 7a) but increased it in arteries from 
orchidectomized rats (Fig. 7b). 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Effect of furegrelate on the basal and EFS-induced PGI2 release in 
mesenteric denuded segments from control (A) and orchidectomized (B) rats. Results 
(means + S.E.M) are expressed as pg / mL.mg tissue. Number of animals is indicated in 
parenthesis. * P<0.05 compared with basal PGI2 release. + P<0.05 compared with the 
respective control. 
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DISCUSSION 
 
Recent studies have reported beneficial effects of androgens in cardiovascular function 
in males through different mechanisms that involve NO and prostanoids (Jones et al. 
2004, Martorell et al. 2008). The activation of androgen receptors, expressed in both 
endothelial (Yu et al. 2007) and smooth muscle (Ma et al. 2005) cells, regulates cell-
signalling pathways. However, the vascular effects of male sex hormones have also 
been reported to be independent of androgen receptor activation (Liu et al. 2007) and to 
interact with intracellular calcium regulatory mechanisms, as reported for other sex 
steroids hormones (Zhang et al. 2006).    
The role of NO and prostanoids in regulating vascular tone is well-established (Henrion 
et al. 1997, Ferrer & Osol 1998, Busse & Fleming 2003), and interaction between these 
two systems has been described, particularly that of NO acting on prostanoids release 
(Laemmel et al. 2003, Mollace 2005), however reports describing action of prostanoids 
on the NO system are scarce (Ferrer et al. 2004). TXA2 is one of the most important 
vasoconstrictor prostanoids with stimulatory action on proliferation or hypertrophy of 
vascular smooth muscle cells (Hanasaki et al. 1990), and is implicated as a mediator in 
diseases such as myocardial infarction, hypertension and stroke (FitzGerald et al. 1987, 
Narumiya et al. 1999). We previously reported that endothelial TXA2 release in 
mesenteric artery (Blanco-Rivero et al. 2006a, Blanco-Rivero et al. 2007) and aorta 
(Martorell et al. 2008) was increased in arteries from orchidectomized rats. The fact that 
the levels of testosterone dramatically decreased in orchidectomized rats (Martorell et 
al. 2008), seems to indicate that the vascular effects observed are testosterone-
dependent. However, the involvement of hormones and/or gonadal factors other than 
testosterone can not be ruled out. Thus, vascular endothelial growth factor, basic 
fibroblast growth factor, transforming growth factor b or hyalurodinase with gonadal 
origin (Lissbrant et al. 2003), could all play an important role in vascular function 
(Rahmanian & Heldin 2002).   
Therefore, we now studied the possible modification of EFS-induced TXA2 release by 
endogenous male sex hormones. We found that orchidectomy increased the basal 
TXA2 release, as previously reported in endothelium intact mesenteric arteries from 
comparable animals (Blanco-Rivero et al. 2006a, Blanco-Rivero et al. 2007); it is 
important to mention that basal release in arteries without endothelium was lower than 
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in arteries with intact endothelium, confirming endothelial and smooth muscle cells as 
sources of TXA2 production.  
We have previously demonstrated that EFS induced similar contractile responses in 
mesenteric arteries from control and orchidectomized rats, responses that appear to be 
mediated by NA release  from adrenergic nerve terminals and the subsequent activation 
of α-adrenoceptors (del Carmen Martín et al. 2005); in addition, we found that the 
contractile response to exogenous NA was decreased by orchidectomy (del Carmen 
Martín et al. 2005), suggesting that EFS could increase noradrenaline release in 
arteries from orchidectomized rats; however we later demonstrated that the EFS-
induced NA release was not modified by orchidectomy (Blanco-Rivero. 2006c), which 
indicates that other vasoconstrictor factors could be released when the artery was 
electrically stimulated. Since EFS-induced release of TXA2 has been demonstrated in 
hypertensive rats (Aras-López et al. 2007), we analyzed EFS-induced TXA2 release in 
normotensive rats, as well as the possible role of endogenous male sex hormones on 
that release. We observed that EFS induced a greater TXA2 formation in arteries from 
orchidectomized than control rats, which is in line with reports showing increased TXA2 
release after activation of different receptors (Blanco-Rivero et al. 2006a, Blanco-Rivero 
et al. 2007). This result also indicates that TXA2 could be the contractile factor that is 
released when the artery is electrically stimulated, as previously suggested (Blanco-
Rivero et al. 2006c). Increased TXA2 release would explain the non modification of the 
EFS-induced response in arteries from control and orchidectomized rats, in spite of the 
fact that the NA response was diminished in arteries from the latter animals. 
The next step was to analyze the function of endogenous TXA2 in the EFS-induced 
response, as well as the dependence on male sex hormones. Preincubation with 
furegrelate did not modify the basal tone in arteries from control or orchidectomized 
rats, indicating that endogenous TXA2 does not have a direct effect on vascular tone 
regulation in basal conditions. We showed that furegrelate decreased the EFS-induced 
response in arteries from control rats, but did not modify it in arteries from 
orchidectomized rats, indicating that the effect of endogenous TXA2 on the EFS 
response is under male sex hormone regulation. 
It is widely reported that mesenteric arteries possess nitrergic (Marín & Balfagón 1998, 
del Carmen Martín et al. 2005), sympathetic (Li & Duckles 1992) and sensory 
(Kawasaki et al. 1988) innervations, which modulate vasomotor tone; therefore, the 
EFS-induced contraction is the result of a balance between opposing vasoconstrictor 
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and vasodilator factors (Ferrer & Balfagón 2001, Vanhoutte 1996). Since, in our 
experimental conditions we have demonstrated that sensory innervation does not 
modulate the vasomotor response to EFS (del Carmen Martín et al. 2005), we studied 
whether the differences in the EFS-induced contractions observed in the presence of 
furegrelate were due to alterations in nitrergic and adrenergic innervations.  
Since there is a lack of studies analyzing the effect of TXA2 on neuronal NO release and 
since we previously reported that endogenous prostanoids different from TXA2, i.e. 
PGI2, increased neuronal NO release (Ferrer et al. 2004), it is possible to speculate that 
endogenous TXA2 could regulate neuronal NO and vasomotor function. Therefore, we 
studied the effect of the TXA2 synthesis inhibitor furegrelate, on the release and function 
of neuronal NO, as well as the dependence on endogenous male sex hormones. We 
found that in arteries from control rats, furegrelate increased the neuronal NO release, 
which is in line with reports describing an inhibitory effect of TXA2 on inducible (Yamada 
et al. 2003) and on endothelial (Miyamoto et al. 2007) NO release. The vasodilator 
response induced by the NO donor, sodium nitroprusside, was also increased by 
furegrelate, showing that endogenous TXA2 negatively modulates both the release and 
the vasodilator effect of neuronal NO. These results could also explain the decreased 
EFS-induced contraction in the presence of furegrelate, but alterations in the release 
and function of neurotransmitters other than NO can not be ruled out. 
Different modulating effects of TXA2 on NA release have been reported, including 
inhibition (Nishihara et al. 2000) and non modification (Rump & Schollmeyer 1989). The 
fact that furegrelate did not modify either NA release or it vasomotor response, as 
previously reported (Hoang et al. 2003, Moldering et al. 1998), indicates that 
endogenous TXA2 does not alter the function of sympathetic innervation in arteries from 
control rats.   
In contrast, in arteries from orchidectomized rats, furegrelate did not modify the basal 
and EFS-induced NO release; since TXA2 formation was greater in arteries from 
orchidectomized than control rats, we used a higher concentration of furegrelate, and 
still obtained similar results. In addition, the vasodilator response induced by sodium 
nitroprusside was not modified by furegrelate. These results show that endogenous 
TXA2 does not regulate the release or function of neuronal NO in arteries from 
orchidectomized rats, in contrast to what occurs in arteries from control rats.  
Regarding noradrenergic neurotransmission, we found that furegrelate modified neither 
NA release nor the vasoconstrictor response induced by exogenous NA, indicating that 
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the function of the sympathetic innervation is not regulated by endogenous TXA2 in 
arteries from orchidectomized rats, as was also observed in arteries from control rats. 
Since TXA2 was higher in arteries from orchidectomized rats, and since that 
endogenous TXA2 did not modify either the release or function of NO or NA, the 
unaltered EFS-induced response observed in the presence of furegrelate could be 
explained through the release of vasodilator factors that would counterbalance the 
vasoconstrictor effect of TXA2.  
One of the more plausible candidates would be PGI2, since cross-talk between TXA2 
and PGI2 systems has been reported (Cheng et al. 2002, Martorell et al. 2008) and joint 
increases in PGI2 and TXA2 synthesis have been shown in pathological conditions 
(FitzGerald 1991, Caughey et al. 2001). Therefore, we measured the production of PGI2 
in the presence of furegrelate in mesenteric arteries from both control and 
orchidectomized rats. First, we found that orchidectomy did not modify either basal or 
EFS-induced PGI2 release, in contrast to the increased PGI2 formation observed in 
aorta from comparable animals (Martorell et al. 2008); these results are in line with 
reports showing smooth muscle (Wang et al. 1993; Ferrer et al. 2004) and/or neuronal 
(Snitsarev et al. 2005) cells as cellular sources of PGI2. Concerning the effect of 
endogenous TXA2 on PGI2 production, we observed that the inhibition of the 
endogenous TXA2 synthesis did not modify the release of PGI2 in arteries from control 
rats, although it did increase PGI2 release in arteries from orchidectomized rats. This 
result reinforced the suggestion that the possible increase in the release of vasodilator 
substances that counterbalance the vasoconstrictor effect of TXA2, although the 
involvement of substances other than PGI2 can not be ruled out. 
In summary, this study demonstrates that non-endothelial TXA2 release is increased in 
mesenteric arteries from orchidectomized rats. The effect of endogenous TXA2 on the 
EFS-induced response is also regulated in a gonad-dependent way, suggesting that 
male sex hormones modulate different simultaneous cell signalling pathways. In arteries 
from control rats, inhibition of TXA2 formation decreases the EFS-induced response by 
increasing neuronal NO release, but in arteries from orchidectomized rats, the EFS-
induced response is unaltered after the inhibition of TXA2 formation, by increasing PGI2 
release.  
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ABSTRACT 
 
Increasing evidence shows that sex hormones exert a protective effect on the 
vasculature, especially in the regulation of the active vasomotor responses. However, 
whether sex hormones affect vascular remodeling is currently unclear. In the present 
study, we tested the hypothesis that testosterone in males and β-estradiol in females 
prevents inward remodeling, possibly through inhibition of the cross-linking enzyme type 
2 transglutaminase (TG2). Small mesenteric arteries were isolated from male and 
female Wistar rats. Using a wire myograph setup, we found a dose dependent 
relaxation to testosterone and β-estradiol, which was inhibited by the competitive nitric 
oxide synthase inhibitor Nω-Nitro-L-arginine methyl ester hydrochloride (L-NAME). This 
confirmed that these hormones were able to induce nitric oxide release. When arteries 
were cannulated, pressurized, and kept in organ culture with endothelin-1 for three days 
we observed inward remodeling. This was significantly inhibited by testosterone in 
males, and by β-estradiol in females. Inward remodeling was also reduced by an 
inhibitor of TG2, both in males and females. In arteries from female rats, endothelin-1 
increased TG2 activity, and this effect was prevented by β-estradiol. We conclude that 
testosterone and β-estradiol prevent constriction-induced inward remodeling. In 
females, this effect could be mediated by the inactivation of TG2. 
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INTRODUCTION 
 
The role of sex hormones has become an important theme in vascular biology during 
the last decades, as accumulating evidence suggests that both male and female sex 
hormones may play protective roles on the vasculature [1]. Many studies have 
demonstrated a beneficial effect of endogenous sex hormones on vascular tone 
regulation, showing for example, that these hormones increase NO release and/or 
bioavailability, decrease the oxidative stress, and reduce the synthesis of 
vasoconstrictor prostanoids [2-5]. Studies regarding the role of sex hormones in 
vascular remodeling have been mainly focused on growth factors and signal cascades 
related to smooth muscle cell proliferation [6-8]. However, little is known about the effect 
of sex hormones on small artery remodeling, which does not necessarily involve cellular 
proliferation.Small arteries constitute the main source of resistance to blood flow in the 
vascular system [9]. Regulation of vascular diameter involves adaptation of both 
vascular tone and structure [10]. Changes in vascular structure include inward 
remodeling, which is characterized by a decrease in the outer and lumen diameter, and 
an increase in the media/lumen ratio [11]. The underlying mechanisms of remodeling 
are still unclear, but it could be the result of a reorganization of the extracellular matrix, 
with either a repositioning of the cells or a balanced process of apoptosis and 
proliferation. Inward remodeling has been described in hypertension, in response to low 
blood flow, and after chronic vasoconstriction [12-14]. It is one of the mechanisms 
responsible for the increased vascular resistance in hypertension and has a prognostic 
value for cardiovascular disease [15, 16].In previous work from this group, it has been 
reported that type 2 transglutaminase (TG2) plays a role in the vascular remodeling 
associated to chronic vasoconstriction in vitro [17], hypertension [18], and reduced 
blood flow [19]. The expression of TG2 occurs in several cell types, including the 
endothelium and smooth muscle cells [20]. TG2 is located both in- and outside of the 
cell [21] and it has been suggested that its release depends on its activation [22]. An 
important function of TG2 is the cross-linking of a glutamine residue of a protein/peptide 
substrate to the primary amino group of a lysine residue [23]. Thus, a large variety of 
proteins can provide a substrate for the enzyme. The physiological role of TG2 is still 
being discussed, although its involvement on cell adhesion, wound healing, apoptosis, 
and matrix reorganization is currently accepted [21]. The activity of TG2 is dependent 
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on calcium, and can be inhibited by nitric oxide (NO) and GTP [24, 25]. 
Hence, the objective of the present study was to investigate the effect of testosterone 
and β-estradiol on constriction-induced remodeling in mesenteric arteries from male and 
female rats respectively. In addition, we studied the possible role of TG2 in this process. 
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MATERIAL AND METHODS 
 
Rats and vessel isolation 
Small mesenteric arteries from 4 months-old male and female Wistar rats were used. 
Rats were anesthetized by isoflurane inhalation and sacrificed by decapitation. Artery 
segments from second and third branches of the mesenteric artery were carefully 
dissected out and immediately placed in cold MOPS buffer. Arteries were cut in equal-
sized pieces where one segment was randomly assigned as control and other 
segments subjected to various interventions. All experiments were approved by the 
Committee for Animal Experiments of the Academic Medical Centre Amsterdam 
(permission 102242).  
 
Wire myograph 
Dose-response relationships to sex hormones were recorded using a Mulvany wire 
myograph (Danish Myo Technology). After dissection vessels were placed in the organ 
bath containing physiological saline solution (PSS) continuously gassed with 5% 
CO2/95% O2 air at pH 7.4 and 37ºC. Arteries were mounted on two 40-µm wires and 
stretched up to its optimal position (normal distension, 0.9 L100), which was estimated 
according to the Laplace relationship (pressure = tension/radius) that gives an 
estimated diameter at 100 mmHg [26]. Segments were exposed to PSS containing 120 
mmol/l KCl and 10µmol/l norepinephrine to assess its maximum contractility. After a 
washout period, the integrity of the endothelium was assessed by adding 10µmol/l 
methacholine to segments precontracted with 10 µmol/l norepinephrine. Then, 
concentration response curves to β-estradiol (0.1nmol/l -10µmol/l) in females, or 
testosterone (0.1nmol-10µmol/l) in males were recorded on segments precontracted 
with 10µmol/l norepinephrine. To determine the contribution of nitric oxide (NO) in this 
response the competitive NO synthase inhibitor Nω-Nitro-L-arginine methyl ester 
hydrochloride (L-NAME, 100µmol/l) was added to the bath 30 minutes prior to the 
concentration response curves. 
 
Pressure myograph and remodeling 
Vessels were also studied using a pressure myograph, where segments were tied to 
glass cannulas on both ends and pressurized using an electro-pneumatic converter 
(model T5200, Fairchild). The organ bath was mounted on top of a microscope and 
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equipped with a digital camera that was connected to a computer. The internal diameter 
of the vessels was measured using MatLab software (Math Works, USA) and recorded 
continuously. The temperature of the setup was kept at 37ºC. Vessels were kept in 
Leibovitz medium containing 1% of a mix of antibiotic-antimycotic solution. The 
perfusate but not the superfusate was supplemented with 10% heat-inactivated Fetal 
Calf Serum (HI-FCS). FCS may contain around 20 pg/ml estrogen [27], which 
corresponds to a final concentration of ~ 7 pmol/l. After checking for leaks, a passive 
pressure-diameter curve (10-120mmHg) was performed in the presence of papaverine 
(0.1mmol/l) to rule out the influence of vasomotor tone. After washing out papaverine, 
the superfusate was supplemented with different compounds depending on the 
experimental group. Three different groups were used in each gender. For males, the 
groups consisted of 10nmol/l endothelin-1, 10nmol/l endothelin-1 plus 10nmol/l 
testosterone, and 10nmol/l endothelin-1 plus 10µmol/l L682.777. For females, the 
groups consisted of 10nmol/l endothelin-1, 10nmol/l endothelin-1 plus 10nmol/l β-
estradiol and 10nmol/l endothelin-1 plus 10µ mol/l L682.777. Arteries were maintained 
during three days in these conditions at 80 mmHg, with the medium refreshed daily. At 
the end of the culture period, a second passive pressure-diameter curve (10-120mmHg) 
was recorded for each artery after full dilation with 0.1 mmol/l papaverine.  
 
Determination of TG2 activity 
TG2 activity was visualized using the pseudo-substrate cadaverine linked to FITC 
(fluorescein isothiocyanate). Arteries were mounted in a pressure myograph, using 
Dulbecco's modified eagle medium (DMEM) medium supplemented with 10% HI-FCS. 
In all groups FITC-cadaverine (100µmol/l) was added to the superfusate which was also 
supplemented with different compounds depending on the group. Three different groups 
were used in each gender: control, 10nmol/l endothelin-1, and 10nmol/l endothelin-1 
plus 10nmol/l testosterone in males; and control, 10nmol/l endothelin-1 and 10nmol/l 
endothelin-1 plus 10nmol/l β-estradiol in females. The pressure was set at 80mmHg 
and the myographs were placed in the dark in an incubator at 37ºC during 24 hours. 
After washing with PBS during 5 minutes and fixation with formaldehyde for 10 minutes, 
vessels were mounted on glass slides using Vectashield/DAPI and imaged on a 
confocal microscope (Leica TCS SP2). Laser and photomultiplier settings were 
unchanged during the acquisition of images from the different groups in each rat. TG2 
activity was quantified using ImageJ software. Data were corrected for vessel size and 
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depicted in arbitrary units. 
 
Calculations and statistics 
From each rat, 3-4 equal sized segments were obtained and studied in simultaneous 
experiments, being assigned to different experimental groups. Results are expressed as 
mean ± SEM for the number of animals indicated. T-tests were used to compare data, 
followed by Bonferroni corrections as appropriate. To compare pressure-diameter 
relations on day 0 vs. day 3, two-way Repeated-Measures ANOVAs were also 
performed.  Data were considered significant when p < 0.05. 
 
Chemicals and solutions 
Leibovitz medium, DMEM medium and the antibiotic-antimycotic solution were obtained 
from GIBCO (Breda, The Netherlands). FCS was obtained from BioWhitaker (Verviers, 
Belgium). Papaverine, norepinephrine, methacholine, L-NAME and β-estradiol were 
obtained from Sigma (Sigma-Aldrich, St. Louis, MO) and testosterone was obtained 
from Fluka (Sigma-Aldrich, St. Louis, MO). Endothelin-1 was obtained from Bachem 
(Bubendorf, Switzerland), L682.777. was obtained from Zedira, (Darmstadt, Germany). 
Salts were obtained from Merck (Darmstadt, Germany). FITC-cadaverine was obtained 
from AnaSpec Inc. (Fremont, CA). Vectachield/DAPI was obtained from Vector 
Laboratories (Burlingame, CA). MOPS buffer was composed of (in mmol/l): 145 NaCl, 
4.7 KCl, 1.2 NaH2PO4, 1.2 MgSO4, 2 CaCl2, 3 3-(N-morpholino) propanesulfonic acid, 
5 glucose, and 2 pyruvate, pH 7.4. PSS buffer was composed of (in mmol/l) 119 NaCl, 
25 NaHCO3, 4.7 KCl, 1.18 KH2PO4, 1.17 MgSO4, 2.5 CaCl2, 0.027 EDTA and 5.5 
glucose. 
  
102 
 
RESULTS 
 
Vascular reactivity 
The acute effect of testosterone and β-estradiol on vascular function was tested in a 
wire myograph setup. Mesenteric arteries were pre-contracted with norepinephrine. 
Then, male vessels were exposed to increasing doses of testosterone. This induced a 
dose dependent relaxation (Figure 1). Segments from female rats were exposed to 
increasing doses of β-estradiol, which also induced dose dependent relaxation. The 
relaxation induced by both sex hormones was attenuated in the presence of the 
competitive NO synthase inhibitor, L-NAME (Figure 1). This shows that both hormones 
induce relaxation through release of NO.  
 
 
 
 
 
 
 
 
 
Figure 1. Testosterone and β-estradiol induced a dose-dependent relaxation in small mesenteric segments 
from male (A) or female (B) rats, respectively. Incubation with L-NAME partially prevented this relaxation in both 
groups. Results (mean ± SEM) are expressed as the percentage of inhibition of contraction induced by 
10µmol/L norepinephrine. Number of animals is indicated in parenthesis. 
 
Vascular remodeling 
To study the effect of physiological concentrations of sex hormones on inward 
remodeling associated with chronic vasoconstriction, we used an organ culture 
approach. Small mesenteric arteries were cannulated and exposed to endothelin-1 for 3 
days. Arteries from both genders showed inward remodeling after the culture period 
(Figures 2 and 3). Remodeling was defined as a difference in the passive diameter 
between the first and the second measurement at a given pressure in each segment.  
When testosterone was also added to the culture medium of male arteries (Figure 2a), 
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or β-estradiol to the culture medium of female arteries (Figure 2b), remodeling was 
reduced. This showed that both sex hormones partially prevent constriction-induced 
vascular remodeling. Remodeling was also partially prevented in both genders by 
incubation with the TG2 inhibitor L682.777 (Figures 3a and 3b), indicating that TG2 is 
involved in the remodeling process. 
 
 
 
 
 
 
 
 
 
 
 
Figure 2. Passive pressure-diameter curves of cannulated small mesenteric arteries were recorded to 
measure remodeling. After the culture period, arteries from both genders incubated with endothelin-1 (ET-
1) showed inward remodeling. (A) When male arteries were also incubated with testosterone, remodeling 
was attenuated. (B) Remodeling was also attenuated by β-estradiol in female arteries. Results are 
expressed as mean ± SEM. Number of animals is indicated in parenthesis. RM Two-way anova: +p<0.05. 
T-test: control vs ET-1, **p<0.01;  ET-1+Testosterone (A) or ET-1+β-estradiol (B) vs. ET-1, #p<0.05, 
##p<0.01. 
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Figure 3. Inward remodeling induced by endothelin-1 (ET-1) was prevented by the TG2 inhibitor 
L682.777 (L682) in both genders (A, B). Results are expressed as mean ± SEM. Number of animals is 
indicated in parenthesis. RM Two-way ANOVA: +p<0.05. T-test: control vs ET-1, **p<0.01; ET-1+L682 vs. 
ET-1, #p<0.05, ##p<0.01. 
 
During the three days of incubation, the constriction induced by endothelin-1 was 
maintained, and this was not modified by coincubation with testosterone, β-estradiol or 
L682.777 (Figure 4). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4. Contraction induced by endothelin-1 expressed as the average internal diameter, was not 
significantly modified by any intervention during the culture period in small mesenteric segments from 
male or female rats. Results are expressed as mean ± SEM. Number of animals is indicated in 
parenthesis. 
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Transglutaminase activity 
Since we found that ET-1-induced remodeling depends on both TG2 and sex 
hormones, we studied the relationship between the sex hormones and TG2 activity. The 
activity of TG2 in the vessel wall is reflected by the incorporation of fluorescent 
cadaverine (FITC-cadaverine), a substrate for TG2 (Figure 5). In males, endothelin-1 
did not significantly increase TG2 activity. Testosterone also did not modify TG2 activity. 
In females, ET-1 induced a significant increase in TG2 activity. This increase was 
completely abolished in vessels incubated with β-estradiol. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Confocal images of small mesenteric segments from male and female rats.  TG2 activity is 
shown in green, detected by the incorporation of the pseudo substrate FITC-cadaverine. TG2 activation 
induced by ET-1 was prevented by β-estradiol in segments from female rats. In segments from male rats, 
TG2 was not activated by ET-1, and this was not modified by testosterone. Data are expressed as mean 
± SEM. Number of animals is indicated in parenthesis. *p<0.05 Control vs ET-1.  +p<0.05, Control vs ET-
1+ β-estradiol.  
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DISCUSSION 
 
The present study aimed to investigate the effect of sex hormones on vascular tone and 
structure. Clinical and epidemiological studies have shown an inverse correlation 
between serum sex hormones levels and cardiovascular disease in both genders [28-
30]. Serum levels of sex hormones decrease with age, and evidence suggests that they 
play an important role in the regulation of vascular function [1, 31-33]. Thus, low serum 
levels are independently related to cardiovascular disease in both genders [34-36]. The 
protective effect of sex hormones can be attributed to several of their actions, such as 
modulation of the lipid profile, vascular tone and vascular structure [2, 31, 33]. Even so, 
studies concerning vascular structure and sex hormones have focused mainly on the 
hypertrophic remodeling, and there are few data concerning the effect of sex hormones 
on inward remodeling [37-39]. Here we tested whether testosterone and β-estradiol (the 
main male and female sex hormones, respectively) could prevent vascular inward 
remodeling induced by three days of maintained constriction with endothelin-1 under 
pressurized conditions. We observed that in both genders, corresponding hormones 
were able to inhibit vascular remodeling.  
Previous work showed that an active, persistent constriction is necessary to induce 
eutrophic inward remodelling. Consequently, remodeling could be prevented by 
vasodilators such as papaverine and verapamil [13]. Considering these data, the 
reported effect of the hormones could be related to its vasodilator properties. The wire 
myograph experiments showed that both sex hormones indeed induce a dose-
dependent relaxation. This relaxation was inhibited by L-NAME, indicating it is mediated 
by NO. However, the analysis of the average tone of the pressurized arteries during the 
three days of organoid culture revealed that constriction was similar during the culture 
period in all groups. This indicates that the inhibitory effect of sex hormones on inward 
remodeling was not related to its vasodilator effect.  
Vascular remodeling of small arteries induced by reduced blood flow, hypertension, and 
exposure to vasoconstrictors depends on TG2 [17-19]. Thus, inhibition of the activity of 
the enzyme prevents vascular remodeling [17, 19, 40], an observation that was 
confirmed in the present study. Although the way by which TG2 exerts its effect on 
remodeling is not totally clear, TG2 could play a role in providing mechanical strength to 
the vessel wall by cross-linking structural proteins within the extracellular matrix. It has 
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been suggested that acting this way, TG2 could fixate the constricted artery in a more 
narrowed state [13, 41].  Some proteins have been found to be substrates for TG2 in 
the extracellular matrix of remodeling-activated smooth muscle cells, such as 
fibronectin, collagen alpha-1 chain, fibulin-2 and nidogen-1 precursors [42]. Other data 
from the same publication showed that TG2 activity associated to remodeling is located 
to the cell membrane, suggesting that translocation of the enzyme is necessary to 
induce remodeling. Once activated and located in the extracellular cell surface, TG2 
could cross-link its extracellular substrates. 
We found that in females, endothelin-1 increased TG2 activity. This increase in TG2 
activity was completely inhibited by addition of β-estradiol. This suggests that the 
inhibitory effect of β-estradiol on remodeling is mediated by modulation of TG2 activity.  
An attractive hypothesis is that the effect of β-estradiol on TG2 is mediated by NO. It 
has been reported that NO release induced by sex hormones induces S-nitrosilation of 
different proteins [43-45]. It has also been reported that TG2 can be inactivated by S-
nitrosylation [24, 46]. In fact, TG2 activation and associated remodeling can be inhibited 
by NO donors [17, 42]. Thus, despite the fact that the level of tone was not significantly 
affected by β-estradiol during culture, we speculate that β-estradiol inhibits TG2 activity 
through release of NO. 
In males, endothelin-1 did not significantly increase TG2 activity, and testosterone did 
not modify this.  Thus, although testosterone prevented inward remodeling, it does not 
seem to act through modulation of TG2 activity. Further work is therefore necessary to 
clarify the inhibitory effects of testosterone on remodeling in males. Conversion of 
testosterone to β-estradiol trough aromatase, which is present in both smooth muscle 
and endothelial cells [47] could be speculated upon. However, since neither endothelin-
1 nor testosterone affected TG2 activity, a similar pathway in males as in females via 
the conversion of testosterone to β-estradiol appears unlikely. Taken together, these 
data show that the mechanism of action of sex hormones is different in each gender. 
The incidence of cardiovascular disease is lower in women compared to age-matched 
men but it increases notably in women after menopause [36, 48]. This effect led to the 
idea that female sex hormones were vascular protective while male sex hormones were 
deleterious although more recent evidence indicates that also male sex hormones play 
a preventive role in the vascular function [33]. Nevertheless, the way by which sex 
hormones from both genders exert this protection is different, and often female sex 
hormones seem to be more efficient in this respect. Interestingly, regarding the 
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stiffening of the vessel wall, women exhibit a greater age-related rise in arterial stiffness 
after menopause compared to aged matched men [38], and this difference seems to be 
due to the intrinsic gender differences of the arteries, that become evident when the sex 
steroid secretion is low. Nevertheless, sex hormones also modulate this stiffness [37]. 
Thus, apart from the differences in the action of the hormones, specific gender 
properties of the tissue may determine the way of action of sex hormones. 
We conclude that physiological concentrations of testosterone in males and β-estradiol 
in females prevent constriction-induced remodeling.  This effect does not seem to be 
due to the vasoactive action of sex hormones. In females, the beneficial effect of β-
estradiol may be due to the inhibition of TG2. These observations could be of relevance 
for the treatment of human cardiovascular disease through hormone replacement; since 
the process of small artery inward remodeling that is seen in hypertension [9] may be 
reversible at its early stages [49]. Studies in humans on large arteries have also shown 
an inverse relation between serum hormone levels and arterial stiffness, which can be 
reversed when serum levels are restored [37]. Further studies should therefore address 
the possibility that the hormone replacement therapy could reverse or at least prevent 
vascular remodeling. 
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CONCLUSIONS 
The results presented in this thesis allow to conclude that male sex hormones influence 
vascular tone and vascular structure. 
Regarding the neuronal control of vascular tone the results show that: 
• Orchidectomy does not alter NA release induced by EFS, but it does increase the 
EFS-induced TXA2 release, suggesting that TXA2 could be the contractile factor that 
maintains the EFS-induced vasoconstrictor response in orchidectomized animals. 
• Orchidectomy modifies the role of TXA2 in the EFs-induced response: 
- In arteries from control rats, inhibition of TXA2 synthesis decreases the 
vasoconstrictor response to EFS, not only because the vasoconstrictor effect 
of TXA2 is eliminated, but also because this inhibition increases the release 
and the response to NO. 
- In arteries from orchidectomized rats, inhibition of TXA2 synthesis does not 
alter the response to EFS because the absence of TXA2 is counterbalanced by 
a high increase in PGI2 production, which mediates vasoconstriction. 
• Post-synaptic β-adrenoceptor function in smooth muscle cells is not modulated by 
endogenous male sex hormones, as the response to exogenous NA, the NO donor 
SNP or clenbuterol is not modified by orchidectomy. 
• Endogenous male sex hormones modulate the function of pre-synaptic β-
adrenoceptors. In orchidectomized rats, pre-synaptic β-adrenoceptor activation 
induces an increase in the release of NA and neuronal NO that compensate each 
other so that the vasoconstrictor response to EFS is not altered. 
Regarding vascular structure it was found that: 
• Physiological concentrations of testosterone inhibit inward remodeling induced by 
chronic vasoconstriction in small mesenteric arteries from male rats. 
• The preventive effect of testosterone on vascular remodeling may be due to 
mechanisms different from TG2 inactivation. 
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CONCLUSIONES 
Los resultados de esta tesis permiten afirmar que el control del tono y la estructura 
vasculares están bajo la influencia de las hormonas sexuales masculinas. 
Con respecto al control neuronal del tono vascular los resultados muestran que: 
• La orquidectomía no modifica la liberación de NA inducida por EE, aunque si 
incrementa la liberación de TXA2, lo cual sugiere que este prostanoide podría 
compensar la disminución del efecto vasoconstrictor de la NA en animales 
orquidectomizados manteniendo la respuesta a EE.  
• La orquidectomía modifica el papel del TXA2 en la respuesta contráctil inducida 
por EE: 
- En arterias de ratas controles, la inhibición de la síntesis de TXA2 
disminuye la respuesta vasoconstrictora a EE, no sólo porque se elimina 
el efecto vasoconstrictor del TXA2 sino también porque esta inhibición 
incrementa la liberación y la respuesta a NO. 
- En arterias de ratas orquidectomizadas, la inhibición de la síntesis de 
TXA2 no modifica la respuesta a EE, porque la ausencia de TXA2 se 
compensa con un incremento en la liberación de PGI2 que tiene un efecto 
vasoconstrictor. 
• La función de los receptores β-adrenérgicos postsinápticos no parece estar 
influenciada por las hormonas sexuales masculinas ya que la respuesta 
vasomotora a NA exógena, al donante de NO (SNP) o al clenbuterol no se ve 
modificada por la orquidectomía. 
• La orquidectomía modula la función de los receptores β-adrenérgicos 
presinápticos. En animales orquidectomizados, la activación de los receptores β-
adrenérgicos induce un incremento en la liberación de NA y NO neuronal cuyos 
efectos vasomotores se compensan, haciendo que finalmente, la respuesta 
vasomotora a la EE no se modifique. 
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Con respecto al control de la estructura vascular, los resultados muestran que: 
• El remodelado hacia el interior inducido por la vasoconstricción mantenida 
durante 3 días disminuye en presencia de concentraciones fisiológicas de 
testosterona en arterias de resistencia de ratas macho. 
• El efecto preventivo de la testosterona en machos parece no deberse a la 
inhibición de la enzima TG2. 
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LIST OF ABBREVIATIONS 
3H Tritium 
AA Arachidonic acid 
Ach Acetylcholine 
ADRF Adipose derived relaxing factor 
ANOVA Analysis of variance 
ATP Adenosine triphosphate 
cAMP Cyclic adenosine 
monophosphate 
cGMP Cyclic guanosine 
monophosphate 
CGRP calcitonin gene-related peptide 
Clen Clenbuterol 
COX Cyclooxigenase 
CRLR Calcitonin receptor-like receptor 
DAF Diaminofluorescein 
DAG Diacylglycerol 
DHEA Dehydroepiandrosterone 
DMEM Dulbecco's modified eagle 
medium 
ECM Extracellular cell matrix 
EDHF Endothelium derived 
hyperpolarizing factor 
EFS Electrical Field Stimulation 
eNOS Endotelial nitric oxide synthase 
ET-1 Endothelin-1 
FCS Fetal calf serum 
FITC Fluorescein isothiocyanate 
GTP Guanosine triphosphate 
HI Heat-inactivated 
iNOS Inducible nitric oxide synthase 
IP3 Inositol triphosphate 
K+ Potassium 
KHS Krebs-Henseleit solution 
L-NAME Nω-Nitro-L-arginine methyl ester 
hydrochloride 
L-NMMA L-NG-monomethyl arginine 
NA Noradrenaline 
nNOS Neuronal nitric oxide synthase 
NO Nitric Oxide 
NPY Neuropeptide Y 
O2- Superoxide anion 
ONOO- Peroxynitrite 
PGD Prostaglandin D 
PGE2 Prostaglandin E2 
PGE2 Prostaglandin E2 
PGF2α Prostaglandin F2α 
PGG2 Prostaglandin G2 
PGH2 Prostaglandin H2 
PGI2 Prostaglandin I2 
PIP2 Phosphatidyl-inositol 
bisphosphate 
PKC Protein kinase C 
PKG Protein kinase G 
PLA2 Phospholipase A2 
PLC Phospholipase C 
Prop Propanolol 
PSS Physiological saline solution 
RAMP1 Receptor-affinity-modifying 
protein 1 
ROS Reactive Oxigen Species 
SEM Standard error of the media 
SNP Sodium nitroprusside 
TG2 Transglutaminase 2 
TXA2 Thromboxane A2 
TXB2 Thromboxane B2 
VIP Vasoactive intestinal polypeptide 
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